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1INTRODUCTION
Microorganisms particularly bacterias occupy all imaginable ecological
niches and their importance cannot be overemphazised. Although majority of bacterias
are beneficial, some harm humans and have troubled society over the millennia. The
discovery and clinical applications of antibiotics and antimicrobial chemotherapeutic
agents was instrumental in reducing the mortality and morbidity due to bacterial
infections. But the emergence and dissemination of superbugs has always been a global
threat for control and treatment of infectious disease. The latest described superbug was
NDM (New Delhi Metallo beta Lactamases), confer resistance to Penicillinins,
Cephalosporins and Carbapenems.
Enterobacteriaceae family are the prime colonisers of the lower Gastro
intestinal tract of humans and other vertebrates and also widely dispersed in
environment and, spread easily among humans. They are the most important clinically
significant bacterial pathogens in both nosocomial and community settings. They
account for nearly 70% of urinary tract infections and 50% of septicaemia cases and are
also responsible for a significant percentage of Alimentary tract infections1. These
infections may be sporadic or occur as outbreak.
Members of the family Enterobacteriaceae are gram-negative, non
acid fast, non–spore forming, facultative anaerobes .These organisms are able to convert
nitrate to nitrite by reduction, and able to generate catalase, but not oxidase, and are
motile by peritrichate flagella or non-motile. They account for 80% of clinically
momentous isolates of Gram negative bacteria and 50% of clinically significant bacteria
2in microbiological laboratories, majority of them are urinary isolates1. These infections
affect normal population as well as people with pre-existing illness.
Antibiotic treatment, using beta lactams is the stronghold therapy for Infections
due to pathogenic Enterobacteriaceae. Antibiotic resistance among Enterobacteriaceae
isolates, is a major health problem worldwide. Among the different types of drug
resistance, multidrug-resistant (MDR) Gram negative bacteria is responsible for the
greatest risk to human health because the promptness of development of drug résistance
is much  faster in Gram negative bacteria than of Gram positive bacteria as well as
presence of only  few drugs  to treat these resistant bacterial infections.
Constant exposure of the bacterial pathogens to multiple antimicrobial agents
has induced  mutations that has lead on to the development of various drug resistant
mechanisms for their survival .These mutant  genes  encoding enzymes capable of
hydrolysing  beta lactam antimicrobial agents in these bacteria, show poor activity
against penicillins  and cephalosporin   antibiotics thus increasing the spectrum of
difficulty to treat multidrug resistant  bacterial infections.
Carbapenems are a family of beta-lactam antibiotics that exert their bactericidal
action by inhibiting bacterial cell wall synthesis. These antibiotics exhibit a broad
spectrum of activity and stability against various β lactamases produced by gram
negative bacterias, including ESBL and AmpC β lactamases.
Carbapenemases are enzymes, having an ability to hydrolyse and inactivate a
wide range of different antibiotics2,3.The increased use and misuse of   antibiotics   in
human medicine, agriculture and veterinary ,is the primary contributing factor for the
development of this high level resistance. Other key risk factors for acquiring these
3Carbapenemase resistant Enterobacteriacea are admission in transplantation units and
intensive care unit as well as malnutrition, chronic debilitating illness, mechanical
ventilation, prolonged hospitalization and prior surgical interventions 4.
In gram-negative organisms , two different types of Carbapenemase enzymes
are accountable for    resistance to carbapenem antibiotics, one that uses  serine as the
active site amino acid for hydrolysing the carbapenem i.e., serine carbapenemases and
the another type  of carbapenemases that uses zinc  ion at its active site i.e. Metallo-
beta Lactamases or MBL5 .Metallo-Beta Lactamase activity  is inhibited by EDTA
,chelator of  Zinc.
Most prevalent Carbapenemases in Enterobacteriaceae are KPC,VIM  NDM,
and OXA-486 and among this New Delhi metallo beta lactamase, an acquired, newly
described superbug , confering resistance to broad range of antibiotics including
carbapenams which are used as last  resort for the treatment of Multi Drug Resistant
Enterobacteriaceae7,8,9.
These resistance genes are carried either on chromosomes or associated with
mobile DNA elements  , carrying the blaNDM-1 gene, also have upto 14 other genes
that confer resistance to most of the antibiotics including aminoglycosides, macrolides,
and sulphamethoxazole, thus making these isolates multidrug resistant or, pandrug
resistant. These mobile genetic elements also determine their spread by horizontal
transference in clinically relevant gram negative organisms and produce resistant
phenotypes10 Antibiotics available for treating infections with carbapenemase –
producing gram negative bacteria are the polymyxins (including colistin), tigecyclin
and fosfomycin.
4Castanheira et al. reported in 2011 that first case of bla NDM was identified in
Escherichia coli , which was   isolated in New Delhi, capital of India  in 2006 ,While
these pandrug resistant organisms disseminate to 50 countries covering all continents
except South America and Antarctica, the horizontal transferability of the blaNDM-
1gene via plasmids may be responsible for the rapid dissemination of NDM-1producing
pathogens. In Chennai the prevalence rate of blaNDM-1 gene harbouring
Enterobacteriaceae was 30 ℅, in Haryana it was 13 ℅ and in UK it was 44℅.38
Carbapenemase producing Enterobactericeae strains are responsible for increased
morbidity and mortality due to paucity of other treatment options which also enhance
the development of further resistance.11,12
Timely detection and reporting to the clinicians are important for appropriate
management of patients, development of antimicrobial surveillance programmes as well
as for development of newer drugs, can prevent the transmission of this multi drug
resistance.
Modified Hodge test,Combined disk assay,MBL E-test and
Carbepenamase inactivation test  are devised  as phenotypic methods  for
carbapenamase detection.  These assays  shows low sensitivity and specificity for
NDM13. False positive results may occur due to production of CTX-M with reduced
outer membrane permeability. Metallo-beta lactamases are phenotypically detected by
synergy with EDTA, these produce false positive results, therefore conformation by
molecular methods is necessary.
Hence the present study is intended to detect the presence of MBL producing
Enterobacteriaceae and the susceptibility pattern of these strains to other antibiotics in
5clinical isolates in our hospital using both phenotypic and genotypic tests. All the
Enterobacteriaceae isolates are subjected to four different phenotypic methods such as
combined disc assay with Imipenem and EDTA, Modified Hodge test, MBL E test and
carbapenemase inactivation test to find out their effectiveness in the detection of the
production of MBL. The PCR is also performed to detect the presence of blaNDM-1 gene
which is responsible for production of New Delhi Metallo beta lactamases.
62.  AIMS AND OBJUCTIVES
 To systematically screen the clinical isolates of multidrug resistant
Enterobacteriaceae for resistance to Ertapenam.
 To determine MIC by E-test with Ertapenam strip.
 To detect enzymatic activity of Metallo beta lactamase phenotypically
by modified Hodge test ,Combined disc test, MBL E-test and
carbapenemase inactivation test.
 To study the prevalence of blaNDM-1 among carbapenemase
producing Enterobacteriaceae .
73.REVIEW OF LITERATURE:
3.1 Introduction
Carbapenem antibiotics   are decisive drugs, which are considered to be the last resort
antibiotics for the treatment of multi drug resistant bacteria infections37. The end result of
increased  use as well as misuse  of  carbepenems  is  the reason for  the development of  first
carbapenem  resistant Enterobacteriaceae (CRE) in 1993. 33 New Delhi metallo beta
lactamase-1 producing superbugs are the emerging multidrug resistant or pandrug resistant
gram negative bacterial pathogens capable of hydrolysing and inactivating carbapenems., 14.The
infections due to these pandrug resistant organisms pose a complex task  in treatment because
they have  only  limited therapeutic options15. So rapid and  reliable  detection  methods are
mantatory   in patients  infected or colonized with carbepenemase  releasing   strains ,which
also have essential role in  infection control as well as  outbreak investigation.
3.2. Carbapenems:
Carbapenems are beta-lactam antimicrobial agents with a broad spectrum of activity
because of the hydroxyethyl side chain present in it.6 They exibit their bactericidal effect by
inhibiting the synthesis of peptidoglycan,25. The carbapenems were developed to overcome
antibiotic resistance mediated by earlier bacterial beta-lactamase enzymes like ESBL and Amp
C beta lactamases.
3.2.1 Structure of Carbapenem antibiotics:
83.2.2. Mechanism of action
Carbapenems not sucessfully diffuse through the cell membrane, but these antibiotics
enters  the periplasmic space through porins ,bind to PBP1 and PBP2  and permanently acylate
the PBP ,then inhibit peptide cross linking as well as other peptidase reacions and leads to
lysis of the bacterial cell5.They are stable against most plasmid-mediated or chromosomally
mediated β lactamases except those produced by Stenotrophomonas maltophilia and some
strains of Bactericides fragilis.6 The structure of an acyl−enzyme intermediate for Imipenem
helps  the antibiotic to fight against β-lactamases.8
3.2.3. Spectrum of activity of Carbapenams:
Carbapenems have a wide  spectrum  of  activity against Gram-positive, Gram-negative
and anaerobic bacteria  and are often used as end line agents.Imipenam,Panipenam and
Doripenam are most effective antibiotics against Gram positive bacteria and
Meropenam,Biapenam,Ertapenam and Doripenam are slightly more active againt gram
negative bacteria.  More than 90% of Enterobacteriaceae, including those with reduced
susceptibility to third generation Cephalosporins,Cephalosporins with beta lactam inhibitors
Gentamicin and Amikacin,are susceptible to Carbapenems.
3.2.4. Clinical Indications
Imipenem
Imipenem was indicated in infections caused by hospital acquired , multidrug resistant
organisms. Cilastatin, a peptidase inhibitor, should be given with imipenem,because this drug
was hydrolyzed by dihydropeptidases in renal tubules.
9Meropenem
Meropenem is superior to imipenem because of its reduced potential to cause seizures.
The enzyme dipeptidase cannot destroy meropenem.It is also used in the management of
hospital acquired, worrisome infections.
Ertapenem
Ertapenem can be given as a single dose a day because of its long half- life. The unique
antimicrobial spectrum and pharmacokinetic properties of ertapenem make it more suited to
treatment of patients with community acquired resistant organisms and on outpatient
intravenous antimicrobial therapy. It has poor activity against   non fermentors.1
Doripenem
Doripenem  is active against Non fermenters because it harbour sulfamoylamimoethyl-
pyrrolidinylthio group in its side chain. The affinities for penicillin binding proteins are
species specific in doripenem. For example, doripenem has affinity for PBP3 in
Pseudomonas aeruginosa.
Oral carbapenems like tebipenem pivoxil and faropenem are given as prodrugs to
increase intestinal absorption and get activated by host enzymes in the liver or intestinal
wall63,103.
3.2.5. Mechanism of carbapenem  resistance:
Resistance to carbapenems develops
 Due to structural changes within their PBPs.
 Due to production of beta lactamases such as  metallo-beta-lactamases  and serine
containing Carbapenemases , or
 Due to decreased drug entry consequent to  mutations altering the  outer membrane
porins62. Among these three mechanisms, carbapenemase production plays a most
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important role  .As it can be transmitted via plasmids rapid dissemination is possible to
other sensitive bacteria  and poses  a  threat to treatment strategies.60,61
3.3 New Delhi metallo-beta-lactamase-NDM :
The New Delhi metallo-beta-lactamase (NDM) is a challenging, new metallo beta
lactamase isolated worldwide.17 .The gene NDM encodes a 269 amino acids containing protein,
with a molecular   weight about 27.5 kDa16. Till date 13 types of NDM have been identified
(NDM-1 to -14 ).NDM-11 was not assigned to any unique variant26-28. The differences arise as
a result of point mutations within the NDM gene 18-24.  The site of mutation on the gene predicts
the rate of hydrolysis of carbapenams. As the mutations are not located in the active site of the
enzyme, NDM-2 and NDM-3, have similar hydrolytic activity like NDM-1 .  Whereas NDM-
4 has mutations in the region coding for the active site  they cause increased hydrolysis  of
carbapenems.
3.4   The emergence of NDM-History:
The New Delhi metallo-beta-lactamase (NDM-1) was first described by Yong et al. in
December 2009 ,and was named after the City of origin NewDelhi34.The NDM-1 enzyme was
was first isolated  from a Swedish patient of Indian origin who was treated in New Delhi for
gluteal abscess.Subsequently he developed a  multidrug resistant UTI. On returning back to
Sweden he was hospitalised in Orebro, Sweden, in January 2008 ,his urine culture yielded an
isolate of carbapenem resistant Klebsiella pneumonia. Subsequent stool samples from the same
patient, tested in March 2008 yielded a carbapenem resistant strain of Escherichia coli17 due to
genetic transfer of drug resistance. Phenotypic testing of both isolates showed it was due to a
metallo-b-lactamase (MBL) but PCR analysis failed to detect known MBL genes. Further
Cloning and sequencing studies  identify that the resistance was due to a new metallo beta
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lactamase enzyme which shared only 32% identity with VIM-1/2. The novel MBL was
designated NDM-1, as the authors of the report believed the resistance originated from India25.
In March 2010 ,a hospital in Mumbai isolated the newer, blaNDM-1 gene from
most of the Carbapenem  non susceptible bacterias .6 In June 2010, the Centers for Disease
Control and Prevention (CDC)   reported its first three cases of NDM-1 producing
Enterobacteriaceae isolates from patients who  had received recent medical care in India35 .
Three cases of Acinetobacter baumannii harbouring bla NDM-1 were isolated from an
intensive care unit of a hospital in Chennai, in April 2010. First confirmed case of NDM
superbug August 21, 2010, Ontario, Canada had the "superbug" in Brampton. They also found
other confirmed cases in British Columbia and Alberta36.
A study report in August 2010 issue of the journal The Lancet Infectious Diseases
showed the emergence and spread of bacteria carrying the bla NDM -1gene. This reported
about 37 cases in the United Kingdom, 44 isolates with NDM-1 in Chennai, 26 in Haryana,
and 73 in various other sites in Pakistan and India38.
According to Nordman et.al bacterias harbouring NDM-1 are not only reported from
India but also in more than 50 different countries 39, 40. But many of the patients carrying NDM-
1 have a history of medical tourism to India, Pakistan or Bangladesh. NDM-producing bacterial
infection  patients having only intercontinental travel without any association  with health
care delivery system indicates the possibility of cross infection .
Studies conducted by Kumarasamy et,al, Walsh et,al &Yong et,al showed the
epidemiological association, between NDM – 1 positive strains and Indian  subcontinent (10,
43,44)
. Kumarasamy KK et al in India reported that the majority of NDM-1-producing
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Enterobacteriaceae were due to local cross infection (10, 45).
On January 12th 2011, the editor of The Lancet, apologized and acknowledged for
naming a superbug after New Delhi was an “error”(46,47,48)Dortet et al in 2012 highlighted that
the Middle East Asia is a secondary reservoir for NDM-1 positive isolates in which, IncX3
plasmids may play a significant role in transmission58.Several reports from incongruent parts
of the world confirm the possibility of local acquition of  organisms harbouring blaNDM .(49-
57)
Poirel et, al reported that presence of ISAba125 element inbetween bla MBL gene
responsible for  biodiversity and associated global pandemia.
Moellering RC et.al found the presence of associated genes with bla NDM -1 gene
confer fight againt antibiotics, like erythromycin, ciprofloxacillin, rifampicin and
chloramphenicol. It is also accompanied by a gene responsible for the production of  broad
spectrum beta lactamase (CMY -4). 29
Kumarasamy et al, found found the relationship between blaNDM -1 and other genes
such as blaOXA- 23 and armA .10.A similar study by Poirel et al, observed that the NDM - 1
gene in a strain of Citrobacter freundii was accompanied by 9 different types of beta
lactamase32.
Yong et,al and Deshpande et,al highlighted that gene encoding biaNDM-1 is a
plasmid mediated genetic element and capable of   more complex  and  unpredictable spread
than the gene encoding KPC 17,33.
3.5 Factors responsible for production of New Delhi metallo
betalactamases:
The genetic code (blaNDM-1) located on either a plasmid or integrated into the bacterial
chromosome is responsible for the synthesis of the enzyme NDM-1. Researchers suggest that
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environmental pressures, such as the use or overuse of antibiotics, selected for bacteria that
could synthesize this enzyme to survive. Some speculate that because un restricted  use of
antibiotics in many countries, responsible for the development of antibiotic-resistant strains
with NDM-1, some reports suggest India is where this genetic element first developed.
3.6 Methods of transfer of gene encoding NDM:
Tranfer of genes among bacteria is crucial in generating diversity,allowing bacteria to
adopt quickly to changing environments.Mobile genetic elements such as plasmids and
transposons are important agents for transfer of antibiotic resistantance determinants  beween
bacteria .Bacteria can transfer genetic information to get protection against most antibiotics
through mutation or via horizontal transfer by Transformation Transduction or Conjugation.
The most common of these methods of transferring antibiotic resistance is conjugation.
3.7 Mode of transmission:
Yong et, al reported that NDM-1- positive bacteria are capable of colonising the
Gastro-intestinal tract of humans for prolonged periods and are spread through contamination
of water and environmental surfaces.17
The more frequent international travel has contributed additionally to rapid
global dissemination. Kumarasamy et al and Borgia et,al reported that  recent
hospitalisation in, Indian subcontinent is identified as a risk factor for colonisation and
infection  with the NDM-1 producing strain.10,95
The infection is also spread by contaminated medical equipment and by physical contact
between patients and healthcare personnel due to the development of  resistance  against
standard sterilization procedures used on medical equipment. Medical procedures, such as the
prostate biopsy can also play a role in transmission.
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Leverstein et,al. in his study in 2010 reported  travel-associated cases but without any
contact with healthcare systems also  acquired NDM-1 in the community92,93 Kumarasamy
et,al .in 2010 described that  inter-human transmission is likely to play a
major role, via contaminated hands, food or water, particularly in resource poor countries
In India,the majority of NDM-1-producing Enterobacteriaceae were community-
acquired10, 94 .
Nordmann et,al reported that Enterobacteriaceae family members have been
identified as important nosocomial pathogens; infection can lead to severe morbidity and
mortality, particularly in intensive care units (ICU),internal medicine and surgical units, and
pediatric units63 Kumarasamy et,al Nordmann et,al & Poirel et,al reported that NDM
producing organisms responsible for both hospital- and community-acquired infections(10,63,66).
Kumarasamy et,al Nordmann et,al and Wilson ME,et al described that NDM-1
producing bacteria  are responsible for  urinary tract infections, pneumonia, septicaemia,
wound  infections and device-associated infections(10,65.66) .
Bacteria from the Enterobacteriaceae family are the most common cause of urinary
infections. They can also cause bloodstream infections (sepsis), pneumonia, or wound
infections. Clinical manifestations reflect the site of the infection1. Most patients will have
fever and fatigue. If bacteria enter the bloodstream, patients may have toxic symptoms .
Symptoms  are similar to bacteria that express NDM-1 and those that do not express NDM-1.
So patients who harbour NDM-1 will not respond to most conventional antibiotics so they  are
at high risk for complications.
Shenoy et al reported that NDM positive MDRGNB responsible for 33.33% of the total
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Respiratory tract infections and 60% of the total Urinary tract infections67.
NDM -1 positive organism can get colonized in the gut in the absence of any feature of
disease. As most of these organisms are normal commensals of the gut, the screening of these
organisms is a difficult job24.
3.8 RISK FACTORS:
Important risk factors include, prolonged hospital stay,ICU admission, surgical
procedures or the use of medical devices like ventilators or catheters are implicated in the
spread of drug-resistant superbugs also associated with situations such as being transferred
between hospitals  as well as presence of  diabetes mellitus 15,16.
Studies from Yong d.et.al, Mulvey MR et al, Zarfel G et,al. Koh TH et,al ,Gottig S
et.al, Hammerum et,al ,Leverstein et.al,and Kumarasamy et .al  shows that most of the
NDM-1 cases were associated with co-morbidities, advanced medical procedures like organ
transplantation, bone marrow transplantation and cancer chemotherapy and invasive surgical
procedures10, 17, 96-102
. Anjana et al.  described that the overcrowding of a number of critically ill
patients within a relatively small  enclosed area and use of sophisticated invasive machinery such as
ventilators and catheters increase the proportion of patients who are unusually susceptible to
infection and who become reservoirs for their spread67.
3.9 PREVALANCE:
3.9.1 GLOBAL PREVALENCE:
In 2010 Deshpande et, al reported the increasing prevalence of Carbapenemase
producing Enterobacteriaceae from 0% to 8%  between 2006 to Aug 2009 in ICU blood
cultures.
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In 2013 J. Kamile Rasheed et,al  from CDC  reported 8 bacterial strains having NDM-1, and
one isolate with blaNDM-6 gene.
Toleman et, al. in 2015 in Bangladesh,  found the prevalence among blaNDM-1 carrying
GNB was  62% in 2012.
Yamaga et,al in 2015 reported, the prevalence of 47.8%  for KPC, 8.7% for VIM
while  21.7% of bacterial strains have co-existence of the NDM-1 and VIM genes in Nigeria.
Fifty-two carbapenem non-susceptible isolates were screened with NDM-1 specific
primers .Of these,23%  were positive for blaNDM-1 . The 12 isolates positive for bla NDM
PCR were: six Klebsiella pneumoniae, four Escherichia coli and two Enterobacter cloacae.
Full gene sequencing also confirmed that the genes encoded NDM-1 Teo et al.
Moi et .al reported that commonest CRE was NDM-1 seen in 44.4 % of
Enterobacteriaceae followed by KPC accounts for 39.9 % of isolates while OXA-48
responsible for 7.8 % in Singapore.
Zainol et al reported  29% of  NDM-1 producing  Enterobacteriaceae in Malaysia
N. Stoesser et.al reported in 2014 that prevalence of blaNDM  was 7% among
k.pneumoneae strains in Nepal.
Sahin et al. ,reported in 2015  that the prevalence of NDM-1 was 2.3% in Turkey
3.9.2 INDIAN SCENARIO
Various studies from India quoted the prevalence of MBL varying from 8-14% (Bashir et
al8., 2011; Varaiya et al58., 2008; Hirakata et al59., 1998).
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Ram Gopalakrishnan et al in his study on a retrospective review of surveillance over
the period 2001-2008 reported the antimicrobial resistance patterns in Indian hospitals have a
high prevalence that up to 40% of Pseudomonas was resistant to carbapenems.
Vikas kumar et al revealed in his study from North India that 87.17% of resistant isolates
were metallo beta -lactamase producers 64. Noyal et al from Pondicherry reported 50% of the
resistant isolates were MBL producers65.
Study done by walsh et,al. in 2011 in New Delhi showed the prevalence of NDM-1-
producing Shigella boydii and Vibrio cholera in 4%  drinking water samples and 30% of
seepage samples signifying the possibility of  cross infection .
Study by Castenheira et al showed that prevalence of blaNDM-1 was 38.5%  among
CRE in India isolated between 2006-2007.
Mohan et al in 2013 reported the prevalence that among the isolates obtained
during2012,blaNDM-1 gene was present in 53.4% of total isolates  and 84.3% of
Enterobacteriaceae8
Walsh et, al in 2010 reported that prevalence data in India for NDM-1 is 2–8% in his study.
Seema et al.,2011 reported that study undertaken in 2010 at a tertiary referral hospital in
Varanasi in north India, 6.9 % of clinical isolates of Enterobacteriaceae (comprising 30
Escherichia coli, 12 K. pneumoniae and 12 Citrobacter species) were positive for the blaNDM-
1 gene.
Bashir et, al in his study reported that 60% of the metallo beta-lactamase carrying
organisms were found to be NDM-1 producers in 2014 in Srinagar, Jammu & Kashmir.
Indian study by Karthikeyan et, al showed a percentage NDM-1 was 30 per cent in
Chennai, 13 per cent in Haryana and 44 per cent in US among Enterobacteriaceae 38.
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Shenoy et al in 2014 in his study reported the prevalence of NDM-1 positive
Enterobacteriaceae was 48.57℅.
3.9.3 Prevalance in Tamilnadu:
Ramesh et, al in 2014 reported that prevalence of NDM –I among GNB was 12.8% in
Tamil Nadu
Shanthi et, al reported in 2014 that prevalence of NDM-1 gene is 6.55% in
Pseudomonas in Tamil Nadu.
3.10 DETECTION METHODS:
Kumarasamy KK et.al, Yong et, al. & Deshpande et, al described in 2010 that,
Laboratory detection methods of NDM -1 involves, isolation and identification of bacterial
strains by gram staining, biochemical characteristics and cultural characteristics then ,
conventional susceptibility testing followed by enzyme assays and molecular detection of
bla NDM -1. (10, 17, 18,103)
3.10.1 Phenotypic methods:
Phenotypic methods are cost effective, easy to perform, interpret, and introduce into the
work flow of a clinical laboratory. But these methods are not ideal because  they can be affected
by growth medium, phase of reproduction and rate of spontaneous mutations.Therefore,
genotyping techniques are preferentially used worldwide.
3.10.1.1 Kirby Bauer disc diffusion test:
Doyel et, al reported the resistance to ertapenem, sensitivity 97.7% and specificity 100%,
for MEM sensitivity 93% and  specificity 90.7 % and IMP  sensitivity79.1 % and specificity
88.4 % resistance104
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Nordmann et al recommended that Ertapenem is a most appropriate carbapenem for
detecting NDM-1 producers18.
3.10.1.2 Modified hodge test:
The modified Hodge test was a suggested screening assay by the Clinical and
Laboratory Standards Institute (CLSI) for carbapenemase releasing organisms106.
According to CLSI document this test is relatively cheap, rapid and easy to perform and has
been reported to have a detection sensitivity exceeding 90% for KPC-type carbapenemases
and 11% for metallo-β-lactamases.105
Edelstein M, et al reported in 2010 that, MHT only a phenotypic screening test for
detection of hydrolysing activity of Carbapenems , and therefore will not differentiate
various types of carbapenemases. By this method detection of MBL can be difficult that pose
unique challenges in the laboratory31
Doyle D et al in 2012 found that the modified Hodge test had a sensitivity of 98% for
finding carbapenemases particularly KPC, but it was not good for finding metallo- β-
lactamases. The specificity of the test was 93%.33
Thompson et, al in 2010 reported it is a less sensitive and time consuming assay for
detection of MBL activity. 112
Rimrang B et al reported in 2012 that more than 50% of the NDM-1 positive
Enterobacteriaceae strains were MHT-positive than KPC-producing strains111
Andrea Bartolini et,al reported in 2014 that MHT for carbapenemase producers
shows 94% sensitivity and 100% specificity. KPC-producers shows   100%
sensitivity, 100% specificity but the NDM-1 positive isolates used to show a distorted
inhibition zone .110
Mochon AB et al reported in 2011 that NDM-1 producers used to give
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less strongly positive MHT results.109
Diana Doyle et al reported that the specificity  and , sensitivity of carbapenemase-
negative isolates were 93% and 12 %. The sensitivity for KPC producers was 98% and 93%
for OXA-48-like enzyme producers but the sensitivity is only for NDM producers was
12%104
Arif Sultan et.al reported in 2013 that sensitivity of Modified Hodge Test was 42.8%,
and specificity was 69.8% with a positive predictive value of 94.2% and a negative predictive
value of 9.6%. 108
,
Nor Zanariah et, al reported that the sensitivity and specificity of the MHT for
NDM-1 producers among Enterobacteriaceae was 100% and 40%, respectively.107
Tzouvelekis et al reported that sensitivity for modified Hodge test was 61% and
specificity was 93%.106
3.10.1.3 Combined disc test:
In combined disk assay inhibition zone around the carbapenem disk, is increased in
the presence of chelators like EDTA. This test shows most sensitivity against metallo
beta lactamse production.115
A study conducted by Savitha et, al in 2014 in Karnataka reported that the sensitivity
and specificity for EDTA based phenotypic method for MBL detection is 57.9% and
78.94%.113
Doyle et,al reported that sensitivity of combination disk assay was 78% and specificity
was 93%.104
21
3.10.1.4 MBL E-Test:
Yan JJ et.al in his study highlighted incubation of bacterial strain with Etest strip
impregnated with imipenem and imipenem-EDTA combination showing three or more two
fold dilution in the presence of EDTA indicates the production of metallo-beta-lactamase,
Chance of false negative result was more if the MIC of imipenem is less than 4
micrograms/ml 115.
Franklin et.al described that Etest MBL was reliable for screening of the hydrolysing
activity of carbapenemase enzyme.31
Doyle et, al reported that sensitivity of MBL E-test was 63% for NDM-producing
Enterobacteriaceae but specificity was 100%104
Nordmann et, al. described MBL was successfully detected by the EDTA inhibition test,
using E -test strips impregnated with imipenem and imipenem with EDTA. 114
Kaleem F, et al in his study reported that the MBL E test can be used as a
confirmatory test for MBL detection117.
A study by van der Bij et al reported that by comparing the CDT with the E test for
the MBL production the sensitivity and the specificity for the E test was 100% and 95%
respectively118.
3.10.2 Genotypic methods:
Nordmann et, al in 2009 described that phenotypic assays failed to detect isolates
carrying multiple carbapenem resistant genes, which were successfully characterise only by
genotypic analysis.  Phenotypic methods are growth dependent and time- consuming as it
takes 16 – 24 hours to completion, not useful in clinical aspects and interpretation of results
are also subjective6. Therefore, identification and by molecular methods such as real
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time-PCR have been shown to be sensitive and more accurate for identification of
carbapenemase genes.
.
Doyle et.al the reported prevalence likely under represents the problem, because of the
decreased sensitivity of the phenotypic methods molecular methods are more sturdy
also found that PCR has a sensitivity and specificity of 100% for NDM detection. 119
Doyle D et al in 2012 evaluated the performance of the in-house multiplex PCR is
highly sensitive and specific for the recognition of blaKPC, blaNDM, blaOXA-48-like,
blaVIM, and blaIMP 119.
Kaesse M et al in 2012 found that the sensitivity of polymerase chain reaction was 100% for
blaKPC, blaVIM, blaNDM, and blaOXA-48.124
3.11 TREATMENT:
Kumarasamy et,al highlighted  that Colistin  have good in vitro activity against
NDM-producing  isolates ,have 89%–100% susceptibility and for Tigecycline susceptibility
is about 56-67% 10
Tigecycline posses good outcome in 70% of the patients infected with
carbapenemase producers, the increase in mortality among patients using tigecycline than
other biocides .120
Susceptibility of Tigecycline against Nonfermenting Gram-negative organisms
was low about 15%, as compared to 60% for Enterobacteriaceae, as reported by Jain et al.41
Jamal et al reported in 2013 that colistin is nephrotoxic, and tigecycline,  a
bacteriostatic drug, so not  suitable in sepsis. In addition, tigecycline is not suitable for
treating urinary tract infections because of ineffective excretion via urine 125.
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Study conducted by Mac Vane SH et al in 2014 compared  Ceftazidime and
Ceftazidime with Avibactam against NDM producing and other beta-lactamase producing
isolates.But they showed negative result against NDM-producing isolates.121
Susceptibility of NDM-releasing strains to fosfomycin was 60.5123 to 78%.124.
Zmarlicka MT et, al in his study he confirmed the need of high dose of doripenem as
infusion  that  produce better response compared to a standard dose of 500 mg fre thrice
daily.
combination therapy   using carbapenems and other compounds shows good response
against NDM producers also suggested that combination therapy should continue to be
included in the treatment strategy against infections due to NDM producers.122
Cobo et, al. described that a combination of tigecycline and colistin synergistic action
in multi drug resistant isolates 126
Livermore DM et, al reported in 2010 that combinations using monobactums such
as aztreonam  which have  a ability to resist  hydrolysis by metallo beta lactamases are
recommended by some studies.  NDM - 1 containing bacterial strain may also have other
carbapenemase like amp C or ESBLs which may hydrolyze monobactams. So inhibitors of
these enzymes (like NXL104) should be used along with combination therapy 127.
Falagas ME et, al. in 2010 reported that Fosfomycin is also suggested for use in
Carbapenemase producing pan resistant Enterobacteriaceae 128.
Tangden et al described that combination of fosfomycin and colistin was found to have
both bactericidal and synergistic activities after 24 hours in a strins resistant to fosfomycin.
Similar activity was seen with a Combination of Rifampin, Meropenem, and Colistin
eventhough both strains are resistant to Rifampin or Meropenem alone.129
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3.12 PROGNOSIS:
Factors determining outcome :
Kumarasamy et; al highlighted in his study that although a drift  towards positive
outcome is more, there are many other  host related factors that contribute to the patient’s
outcome,includes
 immune status of the patient
 underlying co -morbid illness
 appropriate treatment, If the NDM-1-producing bacteria are susceptible to colistin,
the prognosis is usually good
 elimination of underlying problems such as drain or remove abscesses and. infected
necrotic tissues
 the management of invasive devices that might be colonized with the pathogen.
 the patient on respirators, immunocompromised patients, and patient’s in
Intensive-care units have a more guarded prognosis.10
N. Stoesser et, al in 2014 reported that the outbreak-associated mortality was about
64% of inpatient deaths in 25 neonates, in contrast with a hospital-wide contemporaneous
neonatal death rate of 0.7%. The neonatal critical care mortality rates were 46% during the
outbreak period.
In a study by Bores A et al, observed that crude mortality and attributable mortality in
the patients with carbapenemase producing Klebsiella pneumonia bacteraemia was 71.9%
and 50% respectively. 131
In a similar study by Patel G et al, found that mortality among the cases with
carbapenemase resistant Klebsiella pneumoniae was significantly more as compared to
control (40% Vs 20%) .132
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Munoz et,al reported that  mortality rates for K. pneumoniae carbapenemase infections
being between 42% and 53%,20the mortality rate seen with NDM seems staggeringly low.
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4. MATERIALS AND METHODS
In the present study 195 Multidrug resistant Enterobacteriaceae isolates
obtained from various clinical specimens like Pus, Urine, Blood, Sputum, Fluids,
Swabs and vascular catheter tips from various departments in Tirunelveli Medical
college, Tirunelveli were included in this study to establish the prevalence of
blaNDM-1 among them.
4.1 Study area:
The present study was conducted at the Department of Microbiology,
Tirunelveli Medical College.
4.2 Specimen               :
All clinical samples were obtained from Microbiological Laboratory (Blood,
Urine, Pus, Swabs, Stool, Sputum, fluids, catheter tips).
4.3 Sample size :
195 non duplicate clinical isolates of Multidrug Resistant Enterobacteriaceae
isolates in the above specimen.
4.4 Study population:
Samples obtained in the Department of Microbiology in
Tirunelveli Medical College.
4.5 Study period :
8 months from December 2015 to August 2016
4.6 Study design : Prospective study
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4.7 Ethical committee approval:
This study was carried out after approval by the Institutional Scientific and
Ethics Committee.
4.8 Informed consent:
Informed consent was obtained from all persons involved in the study.
4.9 Proforma:
A filled in proforma was collected from the patients with details like name,
age, sex, ward, clinical diagnosis, risk factors, surgical interventions, hospital stay and
other parameters relevant to the study.
4.10 Methodology:
4.10.1Sample collection and processing:
A total of 2514 samples received at Microbiological laboratory were screened
during the study period. Of which 425 isolates were Enterobacteriaceae. Out of this,
195 isolates were multidrug resistant isolates, resistant to more than three groups of
antibiotics detected by Kirby-Bauer disc diffusion technique with beta lactam and
non-beta lactam antibiotic containing discs.  Drug susceptibility was interpreted
according to CLSI guidelines. Carbapenem resistance was detected by Kirby Bauer
disc diffusion test using Ertapenem disc and E-test. Those isolates were subjected to
metallo beta lactamase detection methods such as Modified Hodge test, Combined
disc test(CDT), MBL E-test, and Carbapenaemase inactivation test and detection of
blaNDM-1 was done by Multiplex PCR.
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4.10.2 Sample storage
MDR Enterobacteriacea isolates were sub-cultured on to nutrient agar slope
and stored at 2 to 8˚C. The isolates were sub-cultured every fortnight.
4.10.3. Safety precautions
All the procedures were carried out in a Biosafety cabinet with due precautions.
4.10.4 Antibiotic susceptibility testing:
According to the CLSI guidelines the antibiotic susceptibility testing was done
in the entire Enterobacteriaceae isolates by Kirby Bauer disc diffusion method.
4.10.4.1. Inoculum preparation
Inoculum was prepared by direct colony suspension method by taking four to
five well isolated colonies of Enterobacteriaceae from 18-24 hours culture, in peptone
water to achieve a turbid suspension.
4.10.4.2.  Inoculum standardisation
Using Wickerham’s chart the turbidity of the inoculum was adjusted to 0.5
McFarland standard (1.5x108 CFU/ ml).
4.10.4.3.  Kirby-Bauer’s disc diffusion method:
1. Prepare a bacterial inoculum of 0.5 Mc Farland standard
2. A sterile cotton swab was soaked in the inoculum and a lawn culture was made
on to the Muller-Hinton agar (MHA).
3. The panel of antibiotic discs were dispensed (Ceftriaxone disk 30 μg,
Cefotaxime disk 30μg, Ceftazidime disk 30μg, Ceftazidime with clavulanic
acid(30/10)disk,   Gentamicin disk 10μg, Amikacin disk 30 μg ,Ciprofloxacin
disk 5μg,  and Cotrimoxazole disk (1.25/23.75)
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4. Zone of inhibition was recorded and interpreted as per the CSLI guidelines.
4.11.5 Detection of carbapenemase resistance:
4.11.5.1 Disc diffusion method:
According to CLSI guidelines disc diffusion test for Ertapenem(30 μg) was done
for all Multidrug resistant Enterobateriaceae isolates(195 isolates).Zone of inhibition
was also determined according to that.
4.11.5.2 Ertapenam E-test:
It is a quantitative assay for determining MIC concentration of Ertapenem
effective against that isolate.
Procedure:
Ertapenem E-strip was applied to the surface of the lawn culture prepared by
the tested organism and incubated for 18-24 hrs at 35◦C .MIC is calculated at the
point  where the edge of the inhibition eclipse intersects the strip MIC Test strip.
4.11.6 Screening of Metallo beta lactamase production:
All Ertapenem resistant isolates were subjected to metallo beta lactamase
detection methods such as Modified Hodge test, Combined disc test, MBL E-test and
Carbepenamase inhibition test.
4.11.6.1 Modified hodge test:
MHT was performed according to the standard CLSI guidelness.
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Procedure:
 A Muller Hinton agar plate is inoculated with 1:10 dilution of a 0.5 Mac Farland
suspension of E.coli ATCC 25922 bacterial and was streaked for confluent
growth using a swab .
 A 10µg Imipenem disk was placed in the centre of the M-H plate.
 The test isolate was streaked as a straight line from the disc   to the edge of the
plate.
 Plate was incubated at 35◦ ± 2 ◦ for 16-24 hrs.
Interpretation:
Presence of a distorted inhibition zone is interpreted as positive result
for carbapenemase hydrolysis screening.
4.11.6.2 Combined disk test :
Phenotypic detection of MBLs was done by combined disk test.
Procedure:
 Two imipenem disks (10 μg), one containing 10 μl of 0.1M anhydrous EDTA
(292 μg), were placed on a plate inoculated with the test organism.
 Inhibition zones of the Imipenem and Imipenem with EDTA were compared
after 18-24hr of incubation at 37degree.
 A zone diameter difference ≥5 mm between Imipenem  and IPM-EDTA disc
was interpreted as positive results for MBL production31.
4.11.6.3 MBL E Test:
MBL E test strip is used according to the recommendations of the
manufacturer, where one sideof the strip is coated with mixture of Meropenem +
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EDTA and Meropenem in a concentration gradient manner. The strip is made of
porous material and the antibiotics are distributed evenly on either side of the strip. E
test MBL strip has a double sided antibiotic concentration in a range of Meropenem
(MP) 0.125 to 8 µg/ml and Meropenem + EDTA (MPI) 0.032 to 2 µg/ml with a fixed
concentration of EDTA.
Procedure:
1. Prepared a bacterial suspension of 0.5 Mc Farland standard
2. Bacterial suspension was inoculated as a lawn  on to the M-H agar .
3. The MBL E test strip container was taken from the freezer and kept at room
temperature for 15 minutes before opening .
4. The strip was then taken with a sterile forceps or  E test applicator and applied to
the dried agar surface with the MIC scale facing upwards
5. The plate was incubated aerobically for 16-18 hrs at 370C.
Interpretation:
A reduction in the MIC of Meropenem  of three or more 2-fold dilutions in the
presence EDTA is interpreted as a positive test indicative of MBL production.
4.11.6.4 Carbpenamase inactivation test:
Procedure:
 Prepared a test bacterial suspension
 Place 10µg meropenem disc inside the bacterial suspension.
 Incubate for 2hrs at 35◦C
 Place that meropenem disc on M-H agar inoculated with E.coli ATCC 25922
 Incubate for atleast 6hrs at 35◦C.
32
 Read presence or absence of inhibition zone.
Interpretation:
Presence of inhibition zone: no MBL activity
Absence of inhibition zone:   MBL activity
4.11.7 MBL detection by PCR:
The Ertapenem resistant Enterobacteriaceae isolates were further tested for
blaNDM -1 gene by Real-Time PCR. The PCR kit was procured from Helini
Biomolecules, Chennai, India. According to the manufacturer’s instructions, the
procedure was performed.
Table 1: Requirements
Equipment Reagents&
media
Supplies
 Thermocycler
 Analysis software
 Water bath
 Ultracentrifuge
 Vortex mixer
 DNA Extraction
kit
 Helini blaNDM-1
PCR kit
 Nuclease free
water
 Micropipettes
Pippet tips
 1.5 ml microcentrifuge
tubes
 96 well reaction plate
 Spin column
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Storage and stability:
 The bacterial genomic DNA extraction kit was stored at room
temperature.
 The proteinase K and Lysozyme were stored at -20 0 C.
4.11.7.1 Bacterial DNA Extraction:
About 4-6 colonies of the test strains were inoculated in peptone water and
incubated at 370C overnight. 1-1.5 ml of bacterial culture was transferred into the
sterile 2ml centrifuge tube. The tube was centrifuged at 8000rpm for 5 minutes at
room temperature. The supernatant was discarded and the pellet was used for the
DNA extraction.
4.11.7.2 Principle:
The cells are lysed with the enzyme Proteinase K and the nucleases are
inactivated by chaotropic salt. The nucleic acids are bound to special silica fibers in
the spin column tube. The cellular components contaminating the bound nucleic acid
is removed in a series of rapid “wash and spin” steps. The elution releases the nucleic
acids from the silica fiber.
4. 11.7.3 Extraction procedure
 All the steps were done at room temperature.
 The bacterial pellet was suspended in 200µl of phosphate buffered saline and
vortexed for 30 seconds.
 Binding buffer of 400µl and 5µl of internal control template was added to the
suspension.
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 To the above suspension, 20µl of proteinase K was added.
 This was mixed immediately by inverting several times and incubated at 56°C
for 15 minutes in a water bath.
 200µl of Isopropanol was added and vortexed for 15 seconds.
 Entire sample was pipetted into a spin column.
 This was centrifuged for one minute at 13,000 rpm. Flow through was discarded
and the spin column is transferred to a new centrifuge tube.
 500µl of Wash buffer –Ι was added to the spin column.
 This was centrifuged for 60 seconds at 13,000 rpm. Flow through was discarded.
 500µl of Wash buffer-II was added to the spin column.
 This was centrifuged for 60 seconds at 13,000 rpm and flow through was
discarded and centrifuged for an additional one minute at 13,000 rpm  to remove
the residual ethanol.
 The spin column was transferred to a fresh 1.5ml micro centrifuge tube.
 60µl of the Elution buffer (pre-warmed to 56˚C) was added to the centre of the
spin column membrane. Care was taken not to touch the membrane with pipette
tip.
 It was incubated for one minute at room temperature and centrifuged for one
minute at 12,000 rpm.
The column was discarded and purified DNA was stored at -20°C.
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Table:2 blaNDM reaction mix for samples:
S.No Components Volume
1. Probe PCR Master Mix 10µl
2. bla NDM-1 Primer Probe Mix 5µl
3. Internal control Primer Probe Mix 5µl
4. Purified DNA sample 5µl
5. Total reaction volume 25µl
Table   : 3       Primer and probe:
Primer F     :        GTCTGGCAGCACACTTCCTA
R     : CGCCATCCCTGACGATCAAAC
Probe TCTCGACATGCCGGGTTTCGG
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Table:4. Amplification profile for blaNDM-1 gene:
blaNDM-1        = FAM channel
Internal control = HEX channel
Internal control interpretation:
According to the protocols (assuming 100% extraction efficiency) the CT value
is expected within 24-31 for the internal control. This may differ depending on the
extraction efficiency, the quantity of elute added to the PCR reaction and the settings
of machine. If the amplifying sample had high genome copy number, then the internal
control may not produce an amplification plot. This can be interpreted as positive
result rather invalidates it.
` Step Time Temp
Taq enzyme activation 15min 950 C
40cycles
Denaturation 20sec 950 C
Annealing/ Data collection 20sec 560 C
Extension 30sec 720 C
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Table:5. Interpretation of results:
Test Sample Negative
control
Internal
control
Positive
control Interpretation
Positive Negative Positive Positive Positive
Negative Negative Positive Positive Negative
Negative Negative Negative Negative Repeat
Positive Positive Positive Positive Repeat
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5. RESULTS
5.1 The study group:
The study was conducted in the Department of Microbiology, Tirunelveli
Medical College, over a period of 8months from December 2015-August 2016. 2514
samples received at a bacteriological laboratory were screened during the study period.
Of which 425 isolates belonged to the Enterobacteriaceae family. Out of 425 isolates
195 isolates were multidrug resistant. These isolates were subjected to Ertapenem
susceptibility testing by Kirby Bauer disc diffusion test.  And then confirmed with
Ertapenem E- test. Then these resistant   isolates were subjected to MBL detection
methods like Modified Hodge test, CDT, MBL E-test and carbapenemase inactivation
test.   Multiplex PCR is done to detect the presence of   blaNDM-1. The sensitivity
pattern to the antibiotics for the isolates and the other risk factors were analysed.
5.2 Statistical analysis:
All the results obtained were analysed statistically for their completeness,
consistency and accuracy by the parameters like mean and percentages. The results were
analysed by using IBM SPSS statistics 20. The statistical measures were completed with
the help of the statistical software.
The p values were calculated using Chi square test, Fisher exact test and
Mcnemer’s test. The p values less than 0.05 was considered as significant.
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5.3 Age and gender distribution of study isolates:
The study population were analysed based on age and sex. The result
of the analysis are tabulated in Table 6
Table: 6 Age-Sex distribution of study isolates
AGE
(YEARS)
MALE FEMALE TOTAL
NO % NO % NO %
≤10 22 11.28% 13 6.67% 35 19.45%
11-20 2 1.02% 1 O.51% 3 1.53%
21-30 5 2.56% 13 6.67% 18 9.23%
31-40 9 4.61% 4 2.05% 13 6.67%
41-50 18 9.2% 12 6.15% 30 15.38%
51-60 34 17.43% 11 5.64% 45 23.07%
61-70 27 13.84% 9 4.61% 36 18.46%
≥70 14 7.74% 1 0.51% 15 7.69%
TOTAL 131 67% 64 33% 195 100%
The above table shows that among the 195 MDR Enterobacteriaceae isolates,
131 isolates (67%) were from males and the remaining 64 isolates (33%) were from
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females. Male and female ratio was 2.07:1. The mean age was 45.63 years. (Table 6
and Figure.2)
Figure:2 Age and Sex distribution of study isolates
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5.4   Distribution of MDR Enterobacteriaceae among clinical isolates
Table:7 Distribution of MDR Enterobacteriaceae among clinical isolates
ORGANISM No. of isolates
(N=195)
PERCENTAGE(%)
Klebsiella oxytoca 63 32.30
Klebsiella pneumoniae 34 17.43
Escherichia coli 79 40.5
Proteus mirabilis 5 2.56
Proteus vulgaris 14 7.18
Out of 2514 samples screened during the study period, 425 were
Enterobacteriaceae of which 195 samples were MDR Enterobacteriaceae.
Distribution of organisms in this study group were Klebsiella oxytoca in   63 (32.3%)
patients, Klebsiella pneumoniae in 34 (17.43%) of patients, Escherichia coli in 79
(40.5%) patients, Proteus vulgaris in 14 patients (7.2%)
and Proteus mirabilis in 5 (2.6%) patients. Klebsiella species was found to be a
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most common multi drug resistant organism among clinical isolates. (Table :7 &
figure:3)
Figure:3
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5.5 Antibiotic susceptibility pattern of MDR Enterobacteriaceae:
Table: 8 Antibiotic resistances among MDR Enterobacteriaceae
Antibiotics
tested
K.oxytoca
N = 63
K.pneumoniae
N =34
E.coli
N =79
P.vulgaris
N =14
P.mirabilis
N =5
No % No % No % No % No %
Ceftriaxone 55 87.3 34 100 79 100 14 100 5 100
Cefotaxime 63 100 34 100 79 100 14 100 5 100
Ceftazidime 63 100 34 100 79 100 14 100 5 100
Ciprofloxacin 58 92 31 91.1 76 96.2 12 85.7 4 80
Cotrimoxazole 57 90.4 32 94.1 77 97.5 13 92.8 5 100
Amikacin 61 96.8 32 94.1 77 97.5 11 78.6 5 100
Pip/Tazo 12 19.04 16 47 2 2.5 4 28.6 1 20
The above table shows the antibiotic resistance among MDR
Enterobacteriaceae.
5.5.1 Antibiotic resistance among MDR Klebsiella oxytoca:
MDR Klebsiella oxytoca showed 100% resistance to Cefotaxime and
Ceftazidime, 87.3% resistance to Ceftriaxone, 96.8% resistance to amikacin,90.4%
resistance to Cotrimoxazole and 19.4% resistance to Piperacillin /tazobactam
(Table:8,Figure:4)
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Figure:4
5.5.2 Antibiotic resistance among MDR Klebsiella pneumoniae:
Resistance pattern of MDR klebsiella pneumonia is shown in Figure :5. These
isolates were 100% resistant to ceftazidime, ceftriazone and cefotaxime,91.1%
resistance to ciprofloxacin,94.1% resistance to cotrimoxazole and amikacin,47%
resistance to pip/taz. (Table:8)
Figure:5 Antibiotic resistance among Klebsiella pneumoniae:
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5.5.3 Antibiotic resistance among MDR E.coli:
Antibiotic resistance among MDR E-coli isolates are shown Figure:6.The
isolates showed 100% resistance to ceftazidime,ceftriaxone and cefotaxime,97.5%
resistance to cotrimoxazole and amikacin,96.2% resistance to ciprofloxacin and 2.5%
resistance to piperacillin/tazobactam . (Table:8)
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5.5.4  .Antibiotic resistance among MDR Proteus vulgaris:
The antibiotic resistance among MDR Proteus vulgaris is shown in Figure:7.
These isolates showed 100% of resistance to ceftazidime, ceftriaxone and
cefotaxime,85.7% resistance to ciprofloxacin,92.8% sensitivity to
cotrimoxazole,78.6% resistance to amikacin and 28.6% resistance to
piperacillin/tazobactam .(Table:8)
Figure:7
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5.5.5 Antibiotic resistance among MDR Proteus mirabilis:
Antibiotic resistance among MDR proteus mirabilis shown in Figure :8. These
isolates showed 100% resistance to ceftriaxone, ceftazidime, cefotaxime, amikacin and
cotrimoxazole,20% resistance to ertapenem and piperacillin/tazobactam and 80%
resistance to ciprofloxacin. (Table:8)
Figure:8
Antibiotic resistance among MDR Proteus mirabilis
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5.6   Detection of Carbapenem resistance among study isolates:
Table:9a     Detection of Carbapenem Resistance among study isolates
MDR Enterobacteriaceae Isolates      [n=195]
CRE 48       (25.6%)
CSE 147    (75.1%)
CRE: Carbapenem Resistant Enterobacteriaceae
CSE : Carbapenem Sensitive Enterobacteriaceae
Table:9b     Detection of Carbapenem Resistance among study isolates
Organisms
N=48
K.oxytoca K.pneumoniae E.coli P. vulgaris P. mirabilis
No % No % No % No % No %
Ertapenem 25 52.08% 11 22.91% 6 12.5% 5 10.41% 1 20.8%
The above table shows Carbepenem resistant Enterobacteriaceae among
MDR Enterobacteriaceae. Out of 195 isolates 48(24.61%) were resistant and
147(75.1%) isolates were sensitive to ertapenem detected by disk diffusion test and
Ertapenem E-test. (Table:9a)
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Out of 48 Carbapenemase producers 25 isolates (52.08%),11 isolates
(22.91%) were K. pneumoniae,6 isolates (12.5%) were E. coli 5 isolate (10.41%)s
were P. vulgaris and one isolate (20.8%) was P. mirabilis. (Table:9b, Figure:9)
Figure:9   Detection of Carbepenemase resistance among study isolates:
5.7    Detection of blaNDM-1 by PCR
Table:10 Detection of blaNDM-1 by PCR:
Bla NDM PCR
Positive
Bla NDM PCR
Negative
TOTAL
CRE 45 3 48
25
11
6 5
1
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IS T
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E
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No.of Carbepenemase resistant organisms
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The above table shows out of 48 carbpenem non susceptible isolates 45 isolates
(93.75%) were positive for blaNDM-1 PCR. (Table : 10, Figure : 10)
Figure: 10
5.8 Correlation of bla NDM PCR and Modified hodge test:
Table:11 Correlation of Modified Hodge test and blaNDM PCR
MHT bla NDM PCR TOTAL
POSITIVE NEGATIVE
POSITIVE 31 1 32
NEGATIVE 14 2 16
TOTAL 45 3 48
Bla NDM detection by  PCR
BlaNDM PCR Positive
Bla NDM PCR Negative
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The above table shows correlation of blaNDM PCR and MHT. Among the 48
CRE isolates, 31 isolates gave positive result with the MHT. The PCR detected the
presence of MBL gene in 45 isolates. About 31 MHT positive isolates and 14 MHT
negative isolates were PCR positive.
The sensitivity, specificity, positive predictive value and negative predictive
value of MHT in the detection of MBL were 68%, 66.7%, 71.1% and 53.33%
respectively. (Table: 11 and15b and Figure: 11 ). The kappa value denoting the measure
of agreement is poor. (0.254).
Figure:11
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5.9 Correlation of CDT and blaNDM PCR:
Table:12 Correlation of CDT and bla NDM PCR:
CDT bla NDM TOTAL
POSITIVE NEGATIVE
POSITIVE
32 1 33
NEGATIVE
13 2 15
TOTAL
45 3 48
The above table shows among the 48 CRE isolates, 32 isolates gave positive
result with the CDT. The PCR detected the presence of MBL gene in 45 isolates. About
32 CDT positive isolates and 13 CDT negative isolates were PCR positive. The
sensitivity, specificity, positive predictive value and negative predictive value of CDT
in the detection of MBL were 71.1%, 66.7%, 97% and 66.7% respectively. (Table: 12
and 15b and Figure:12). The kappa value denoting the measure of agreement is poor
(0.132)
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Figure:12
5.10 Correlation of MBL Etest and blaNDM PCR for detection of MBL
Table:13 Correlation of MBL E-test with bla NDM PCR
E-TEST bla NDM
TOTAL
POSITIVE NEGATIVE
POSITIVE 36
-
36
NEGATIVE 9 3 12
TOTAL 45 3 48
The above table shows among the 48 CRE isolates, 36 isolates gave positive
result with the MBL E -test. The PCR detected the presence of MBL gene in 45 isolates.
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About 36 MBL E-test positive isolates and 9 MBL E-test negative isolates were PCR
positive.
The sensitivity, specificity, positive predictive value and negative predictive
value of MBL E test in the detection of MBL were 76.5%, 100%, 80% and 100%
respectively. (Table: 13 and 15b and figure 13). The kappa value denoting the measure
of agreement was poor (0.333 ).
Figure:13 Correlation of MBL E-test with bla NDM PCR
0 5 10 15 20 25 30 35 40
POSITIVE
NEGATIVE
bla NDM NEG bla NDM POS
55
5.11 Correlation of carbapenemase Inactivation test and PCR
Table: 14 Correlation of Carbapenemase inactivation test with bla NDM PCR
BlaNDM PCR CI test
TOTAL
POSITIVE NEGATIVE
POSITIVE 42 0 42
NEGATIVE 3 3 6
TOTAL 45 3 48
Figure:14
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The above table shows among the 48 CRE isolates, 46 isolates gave positive
result with carbapenemase inactivation (CIM) test. The PCR detected the presence of
MBL gene in 45 isolates. About 43 MBL CIM test positive isolates and 2 CIM test
negative isolates were PCR positive.
The sensitivity, specificity, positive predictive value and negative predictive value
of CIM test in the detection of MBL were 100%, 33.3%, 100% and 100% respectively.
The kappa value denoting the measure of agreement is good (0.636) (Table: 14 and 15b
and figure 14).
5.12 Comparison of MBL detection phenotypic methods with PCR:
The below table shows that 48 Ertapenem non susceptible, which were evaluated
for the production of MBL by various phenotypic methods like CDT, MHT, MBL E
test and carbapenemase inactivation test. Among them, 31isolates showed MBL
production by MHT and 32 were positive with the CDT.The MBL E test detected about
36 isolates and CIM detected 46 isolates which were considered positive for MBL
production. (Table:15 and Fig:15)
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Table:15 a    Comparison of MBL detection phenotypic methods with PCR:
METHODS MBL PRODUCERS
Bla NDM
PCR
Positive
N=45
percentage Bla NDM PCR
Negative
N=3
percentage
MHT 31 64.58% 1 33.3%
CDT 32 68.75% 1 33.3%
E-TEST 36 75% 0 0%
Carbapenemase
inactivation test
43 95.6 3 100%
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Figure: 15 a Comparison of MBL detection phenotypic methods with PCR:
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5.13 Evaluation of Phenotypic methods of MBL detection:
Table:15 b   Evaluation of Phenotypic methods of MBL detection
Method Sensitivity Speificity Positive
predictive
value
Negative
predictive
value
MHT 68% 66.7% 71.1% 53.33%
CDT 71.1% 66.7% 97% 66.7%
MBL E-test 76.5% 100% 80% 100%
Carbapenemase
inactivation
test
100% 33.3% 100% 100%
The above table shows sensitivity,specificity,positive predictive value and
negative predictive value of phenotypic tests.
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5.14 Table:16 Prevalence of blaNDM-1 among study isolates:
Enterobacteriaceae No of isolates
N= 425
Percentage of isolates
(100%)
MDR Enterobacteriaceae 195 45.88%
Carbapenem resistant
Enterobacteriaceae
48 11.29%
Bla NDM-1 positive isolates 45 10.6%
The above table shows out of 425 Enterobacteriaceae isolates 195 isolates(45.88%)
were Multidrug resistant,among this 48 isolates (11.29%) were resistant to carbepenems
and  from these isolates blaNDM-1 was detected in 45(10.6%) isolates. (Table:16)
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5.15 Table1-17 Distribution of blaNDM-1 among age group:
Age in yrs NDM positive
N=45
Percentage NDM Negative
N=150
%
< 10 5 11 30 20
11-20 0 0 3 1.58
21-30 1 2.2 17 11.3
31-40 3 6.7 10 6.67
41-50 12 26.7 18 12
51-60 15 33.3 30 20
61-70 7 15.6 29 19.3
>70 2 4.5 13 8.7
Total 45 100 150 100
The above table shows distribution of blaNDM positive isolates by age . In the
age group of below 10 years, among 35 isolates five isolates (11%) were positive for
blaNDM.No isolates were positive between 11-20 yrs. One isolate (2.2%) was positive
between 21-30 years among 18 isolates. Three isolates were positive between 31-40
years among 13 isolates. 12 isolates were positive between 41-50 yrs among 30
isolates.15 isolates were positive between 51-60 yrs among 45 isolates and seven
isolates were positive among 61-70 yrs group.2 isolates were positive out of 15 isolates
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belonged to more than 70 yrs group from males and two isolates (50%) were from
females. Mean age for blaNDM positive isolates was 45.73years. (Table :17, Figure:16)
Figure: 16
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5.16 SEX RATIO:
Table: 18 Distribution of blaNDM among gender:
SEX NDM
positive
Percentage NDM
Negative
Percentage
MALE 32 71 99 66
FEMALE 13 29 51 34
TOTAL 45 100 150 100
The above table shows sex distribution of blaNDM positive
Isolates. Male Female ratio is 2.4:1 among positive isolates. (Table: 18 and
Figure: 17)
Figure:17
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5.17 Bla NDM-1 positive pathogens:
The below table shows that out of 48 carbapenamase resistant isolates 45 were
positive for blaNDM PCR.The blaNDM positive organisms were Klebsiella oxytoca in
23(51%) patients, Klebsiella pneumoniae in 9(20%) patients E.coli in 7(15.6%) patients
Proteus mirabilis in one patient(2.22%)and Proteus vulgaris in 5(11%) patients.(Table-
19 & figure 18)
Table:19 Distribution of blaNDM-1 among organisms:
Organisms No of cases %
Kleb.oxytoca 23 51.1
Kleb.pneumoniae 9 20
Prot.mirabilis 1 2.22
Prot.vulgaris 5 11.1
E.coli 7 15.6
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Figure:18
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5.18 Infection wise distribution of blaNDM-1 isolates;
The below table shows that majority of the NDM infections were associated
with wound infection about 27 isolates (60%) followed by UTI in 10 isolates
(22.2%) and Sepsis in 5 (11.1%) isolates, Pulmonary infection in 3 isolates
(6.38%).(Table 21& figure:18)
Table:20 Infections wise distribution of blaNDM-1 positive Isolates
Infections BlaNDM-1positive isolates
NO %
Wound infection 27 60
UTI 10 22.2
Sepsis 5 11.1
Pulmonary infection 3 6.38
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Figure:19
5.19 Distribution of blaNDM from different wards:
Figure:20
Distribution of bla NDM isolates from different wards:
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Table:21 Ward wise distribution of NDM isolates :
WARDS blaNDM isolates
No %
SURGERY 27 60
SNN 2 4.4
UROLOGY 4 8.9
NEPHRO 2 4.4
OG 2 4.4
PICU 1 2.22
ISCU 1 2.22
IMCU 1 2.22
PAED.WARD 1 2.22
THOR.MED 1 2.22
MEDICINE 2 4.4
CAS.WARD 1 2.22
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Above table shows distribution of bla NDM positive organisms among different
wards. Out of 45 positive patients majority(60%) were from surgery ward.( Figure 15
and Table :21 )
5.20 Analysis of risk factors:
5.20.1 Relation of bla NDM  to duration of hospital stay :
Table:23 and figure :21 shows out of 45 blaNDM positive patients 28were
admitted in the hospital for more than 2weeks and 17 patients were admitted in the
hospital for less than two weeks. The association of blaNDM positive isolates with the
duration of stay in hospital was  statistically significant.
P < 0.05
Table:22 Relation with duration of hospital stay:
DURATION
Bla NDM-1
POSITIVE NEGATIVE
<2 WEEKS 17 37.78 154 96.25
>2 WEEKS 28 62.2 6 3.75
TOTAL 45 100 160 100
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Figure:21
5.20.2 Relation of  blaNDM to Diabetes Mellitus:
Table:23 Relation with Diabetes mellitus
DM bla NDM positive bla NDM negative TOTAL
NO % NO %
POSITIVE 26 57.8 37 24.7 63
NEGATIVE 19 42.2 113 75.3 132
TOTAL 45 100 150 100 150
< 2 weeks
>2 weeks
< 2 weeks >2 weeks
blaNDM negative 154 6
blaNDM positive 17 28
Relation of NDM to duration of hospital stay
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Table:23 shows relation of blaNDM to diabetes mellitus .Out of 45 positive patients 26
patients have diabetes mellitus and out of 150 negative patients 37 patients have
diabetes mellits. This association is statistically significant P < 0.05.
Figure:22 Relation of blaNDM positivity and diabetes mellitus:
5.20.3 Relation of blaNDM to exposure of carbapenems:
Table:24 Relation of blaNDM and carbapenem exposure
0
50
100
150
POSITIVE NEGATIVE
26 19
37
113
bla NDM pos bla NDM neg
Carbapenems
administered
Bla NDM positive Bla NDM Negative
No % No %
Yes 23 51.1 16 10.7
No 22 48.09 134 89.3
Total 45 100 150 100
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Figure:22
Table 24 and figure :22 shows relation of carbapenam exposure to blaNDM positive
patients.Out of 45 patients 23 were exposed to carbapenams. This association is
statistically significant P<0.05
YES NO
51.10% 49%
10.70%
89.30%
Relation of blaNDM to exposure of carbapenams
POS NEG
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5.21 Comparison of Tigecyline susceptibility among blaNDM positive and negative
patients.
Table:25 Tigecycline susceptibility
Tigecycline
sensitivity
Bla NDM PCR
Positive Negative
Sensitive 43 95.6% 146 97.33%
Resistant 2 4.4% 4 2.7%
Total 45 100% 150 100
Table 25 and figure 23 shows tigecycline susceptibility among blaNDM-1 positive
and bla NDM negative patients. Out of 45 bla NDM positive patients two (4.4%) were
resistant for tigecycline compared to four (2.7%) patients among blaNDM negative
patients
Figure::24
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5.22 Comparison of colistin susceptibility among blaNDM  positive and blaNDM
negative isolates
Table:26 Colistin susceptibility
The
above table shows that among the 195 MDR Enterobacteriaceae 26 patients were
resistant to colistin in which 12(15.6%) patients were blaNDM
positive.(Table:27,fig:25)
Figure:25 Colistin susceptibility
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6.DISCUSSION
The emergence of infections due to carbapenem resistant Enterobacteriaceae
represents a major public health concern. They are nosocomial and community acquired
pathogens associated with high mortality rates and they have the potential to
disseminate extensively. So early detection and implementation of interventions are
required to control these organisms in health care facilities.
6.1 Prevalence:
Prevalence of blaNDM-1 among Enterobacteriaceae in this study was 10.6%
and among CRE it was 93.75%.
Several studies from India reported that, the prevalence of NDM-1 producers
among CRE was between 31.2% to 91.6% 10.84.89, similar to our study.
Mohan et al reported  84.3% of blaNDM-1 among CRE,this report was concordant
with our report86.Ramesh et al reported comparable  result   of 12.8% among GNB87.
Similar study conducted by Karthikeyan et al found that out of 47 (24%) CRE isolates
26(55.31%) were positive for NDM-1. Parveen et al reported the prevalence of bla
NDM-1 was 70.6% among carbapenemase producing strains. Teo et al reported  that
out of Fifty-two carbapenem  23% were positive  for bla NDM-1.
6.2 Distribution of blaNDM -1 among age and sex:
Out of 195 MDR positive isolates 131(67%) were males and 64 (33%) were
females. Male to female ratio was 2.1:1. Mean age was 45.63 years. The mean age for
blaNDM positive isolates was 45.73 years  and male to female ratio was about
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2.4:1.Rate of infection was 32/131(24.4%) in males which was higher than
females.(20.3%) .
But Karthigeyan et,al  in his study reported that the age range 4-66 yrs with a
mean age of 36 years  and female to male ratio about 2 to 1.
6.3 Distribution of bla NDM-1 among organisms:
In our study out of 45 blaNDM-1 positive isolates ,most common organisms
were Klebsiella oxytoca accounted for 23 isolates(51.15%) followed by Klebsiella
pneumoniae n = 9(20%) ,  E.coli n= 7(15.6%) , proteus vulgaris n=5(11.1%)  and
Proteus mirabilis n=1(2.22%)
Bhaskar et al reported that out of 66 bla NDM-1 positive isolates, 40 isolates were
Klebsiella spp, 6 isolaes from E.coli and 20 isolates from Enterobacter spp similar to
our study report.
Study reports from yong et.al, Kumarasamy et, al. Struelens et.al, Jovcic et.al&
B. Karthikeyan K et.al, showed that presence of NDM-1 has reported from
Enterobacteriaceae as well as Pseudomonas and Acinetobacter species. 10,90,91,38
Kumarasamy KK et,al in his study showed that was Escherichia coli and
Klebsiella pneumonia species accounts for majority of  the production of NDM
compared to other Enterobacteriaceae.10,84
Lascols et al., in 2011 reported that the blaNDM-1 gene was detected in a range of
bacterial strains belongs to the family Enterobacteriaceae including Escherichia coli, K.
pneumoniae, Enterobacter cloacae, Providencia rettgeri and M. morganii
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6.4 Distribution of blaNDM-1 among different specimens:
In our study distribution of bla NDM among specimens were 25(56%) isolates
from pus, 10(22.2%) isolates from urine, 2(4.44%) isolates from blood 2(4.44%)
isolates from sputum ,one from bronchial wash(2.22%),one from drain fluid
(2.22%),one  (2.22%)from biopsy specimen,one (2.22%)from wound swab and one
from catheter tip(2.22%). This study indicated  that the incidence of pyogenic infection
is expected to be highest and was referred from surgical disciplines. Similar to the study
report of Wankhede et al, stated that  Pus (37.29%) was a most predominant specimen
in his study.
6.5 Distribution of blaNDM-1 isolates  among  wards:
Out of 45 blaNDM-1 positive isolates  majority of them 27 isolates(60%)
distributed in surgery  wards followed by 4 isolates(8.9%) from urology ward ,2 isolates
(4.4%) each from SNN,OG  and Medicine ward ,1 isolate(4.4%) each  from PICU,
ISCU, IMCU , paediatric ward ,  thoracic medicine and from casualty ward.
Wankhede et al reported that distribution of organisms in different wards (N=59)
were  Medicine(n=31),OG(N=13),Surgery(n=8), cardiac surgery( n=1), Paediatric
ward(n=1),Ortho(N=4) ,ENT(n=1)
6.6 Risk factors:
In this study group all the isolates were nosocomial isolates. Out of 45 blaNDM -
1 positive isolates  28(62.2%) patients were admitted in the hospital for more than 2
weeks,26 (57.8%) were diabetic patients and 23 positive patients were exposed to
carbapenams.
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Associated risk factors for the  carbapenemase production among
Enterobacteriaceae includes certain situations, such as being transferred between
hospitals or from long-term care centers,  ICU admission, the presence of a central
venous catheter, usage of antibiotics, and having diabetes mellitus [15, 16].
Arindam Ckakraborty et.al study found a significant association (P < 0.05)
between diabetics and infection with blaNDM-1 producers.
6.7 Detection methods:
Out of 2514 samples screened during the study period 425 samples were
Enterobacteriaceae (16.9%) of which 195 samples were MDR Enterobacteriaceae
(45.89%).
6.7.1 Antibiotic susceptibility testing:
All isolates(100%) were resistant to Cefotaxime and Ceftazidime ,183 (93.8%)
were resistant to ceftriaxone 186 (95.4%) were resistant to Amikacin,184(94.3%) were
resistant to Cotrimoxazole,181 (92.8%)were resistant to Ciprofloxacin,48 (24.61%)
were resistant to Ertapenem,39 isolates (20%) were resistant to Piperacillin
/Tazobactam,Tigecycline was resistant to 6  isolates (3.07%),Colistin was resistant to
26 isolates(13.33%) and all isolates were sensitive to Aztreonam. Similar antibiotic
susceptibility profiling was reported by Ramesh et al.
Moellering RC et.al described that presence of other accompanying genes along
with bla NDM -1 for the development of multidrug resistance29
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6.7.2 Detection of carbapenamase producers:
Out of 195 multi drug resistant isolates 48 (24.8%) isolates showed resistance to
ertapenem. MIC was determined by Ertapenam E-test. Out of this 45 (93.75%) were
positive for blaNDM PCR.
Nordmann et al recommended that Ertapenem as the most appropriate
carbapenem for detecting NDM-1 producers18.  Similar report was also found in study
of Parveen et,al that  20.3%  of isolates resistant to Ertapenem  among Klebsiella
species.
6.7.3. Detection of metallobeta lactamses by phenotypic methods:
Modified hodge test was positive for 32 isolates out of which 31 isolates were
positive for bla NDM PCR. .Sensitivity of the test was 68% and specificity was 66.7%
.
Similar study by Tzouvelekis et al shows that the modified Hodge test had a
sensitivity and specificity and of 61% and 93% respectively.106.
Edelstein   M, et al in his study reported that, MHT only screens for a phenotype,
and hence with this method we cannot distinguish between the various carbapenemases
producers. MBLs in  particular can be difficult to detect using these enzymatic assays.
Because of these drawbacks detection of these organisms pose unique challenges in
the laboratory31 Similar report by Bashir et al showed that MHT was positive in 55
of  the 93 meropenem resistant isolates . T Rimrang B et al reported that more than
50% of the NDM-1 positive Enterobacteriaceae isolates were positive for  Hodge test
compared to KPC-producing strains111. Arif Sultan et.al reported in 2013 that
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sensitivity , specificity, positive predictive value and negative predictive value for
Modified Hodge Test are 42.8%,  69.8% , 94.2% and 99.6% respectively. 108
CDT detected 32 out of 45 bla NDM PCR positive isolates with a sensitivity
and specificity of about 71.1% and 66.7%. The sensitivity is relatively similar to the
study of Doyle et, al, in his study he reported the   sensitivity of 78% and specificity is
high about 93%.104
In our study, MBL E test detected 36 out of 45 isolates with a sensitivity and
specificity of about 76.5% and 100% respectively. Specificity is similar to the report of
Doyle et al, reported that sensitivity was 78% when using the MBL Etest and the
specificity was 100%104
Franklin et.al described that MBL - Etest using imipenem and imipenem-EDTA
combination was a dependable test for the detection of enzymatic activity of MBL.116.
Kaleem F, et al in a study reported that the MBL E test can be used to confirm the
MBL117 In our study Carbapenemase inactivation test detected 45(93.75%) of 48 isolates
of which 42 were positive for bla NDM PCR other three isolates may represent other
carbapenemase genes with a sensitivity of about  93.3%   and specificity 33.3%.
Zwaluw et al in his study found a similar report and reported that Carbapenem
inactivation test is a highly sensitive and cost effective screening method and shows
high concordance with PCR, also reported positive and negative predictive value was
100% for Enterobacteriaceae that is similar to our study report.
Nordmann et,al reported that  the main limitation  of these  phenotypic assays are
failure  of detecting  positive isolates with low level antibiotic resistance so give a false
negative  report. 114
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6.7.4 Detection by genotypic methods:
In our study out of 48 carbapenemase resistant Enterobacteriaceae
45 (93.75%) were positive for blaNDM-1 by multiplex PCR. Nordmann et, al in 2009
described that phenotypic tests are unsuccessful in identification of isolates carrying
several genes encoding carbepenemase production, which were effectively assessed
only by genotypic methods.  Phenotypic methods are growth dependent and time-
consuming as it takes 18 – 24 hours to completion, not clinically useful. Results for
these phenotypic assays are also subjective.6
Therefore, identification by molecular methods such as real time-PCR
have been shown to be sensitive and more accurate for identification for detection of
carbapenemase but  sometimes may miss unusual gene types and require trained
personnel and costlier equipments. For the identification of blaNDM-1 gene,
Polymerase chain reaction has been used principally in research laboratories and
reference centers.
In the present study carbapenemase inactivation test is highly sensitive (99.3%)
compared to other tests. Hence we can use this test as a screening tool but the specificity
is very low because of the presence of other carbapenemase encoding genes but MBL
E test is a highly specific test we can use this test for screening of MBL in the absence
of PCR.
Shenoy et.al described that though phenotypic assays are specific, do not
differentiate between chromosomal and plasmid encoded genes therefore
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genotypic characterization should be considered67
Diana Doyle et, al reported that sensitivity and specificity of PCR is 100%
sensitivity and specificity.119
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7. SUMMARY
This study was undertaken at Department of Microbiology, Tirunelveli Medical
College, Tirunelveli for a period of 8 months from   December 2015 August 2016 .Study
group includes 195 MDR Enterobacteriaceae clinical isolates. These isolates were
evaluated for carbapenem resistance by Kirby Bauer disc diffusion method with
ertapenem disc 10µg and by Ertapenem E-test. MBL detection was phenotypically
done by Modified Hodge test, combined disk test, MBL E-test and carbapenemase
inactivation test. The presence of blaNDM-1 gene among the Carbapenem resiatant
isolates were identified by multiplex PCR. Risk factors for acquisition of blaNDM-1
were also analyzed.
o Out of total of 195 isolates of Multidrug resistant Enterobacteriaceae, 131(67%)
were from males and the remaining 64(33%) were from females. Mean age was
45.63years.
o Kirby Bauer disc diffusion test using Ertapenem disc and Ertapenem E-test
detected 48 CRE isolates by measuring the zone size of ≤ 18 mm in diameter
and MIC ≤ 4.
o Multiplex PCR detected bla NDM-1 gene in 45(93.75%) of the 48 CRE isolates.
o MHT detected 32 (64.58%) out of 45 blaNDM-1 positive isolates.
o CDT detected 32 (68.75%) out of 45 blaNDM-1 positive isolates.
o MBL E-test detected 36(75%) out of 45 bla NDM isolates.
o Carbapenemase inactivation test detected 42(93.3%) out of 45 blaNDM-1
positive isolates.
84
o Out of 45 blaNDM-1 positive isolates 32  ( 71% ) blaNDM-1 positive isolates
were from males and 13 ( 29% )were from females.
 Mean age of the blaNDM-1 isolates 45.73 years and male to female ratio was
2.4:1.
o Surgery ward accounted for 27 (70%) of the 45 blaNDM positive isolates while
each two (4.4%%) from SNN,Nephrology ward ,OG and Medicine and each one
from PICU (2.2%),ISCU, IMCU, Pediatric ward and casualty ward   .
 Majority of the NDM infections were associated with wound infection in 27
isolates (60%) followed by UTI in 10 isolates (22.2%) and Sepsis in 5 (11.1%)
isolates, Pulmonary infection in 3 isolates (6.38%)
o Duration of stay at hospital for more than two weeks had statistically significant
association with the infection due to blaNDM isolates.
o Exposure to carbapenems was statistically significant among corresponding
CRE patients.
o BlaNDM positive isolates showed 100% resistance to Ceftazidine, cefotaxime,
ceftazidime-clavulanic acid and ertapenem, 93.3% resistance to ceftrixone, 88.9
% of isolates were resistant to amikacin and cotrimoxazole 93.3% resistance to
ceftriaxone 86.7% resistance to ciprofloxacin. These isolates were 95.5%
sensitive to Tigecycline and 84.5% sensitive to colistin.
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8. CONCLUSION
o This study highlights the prevalence of CRE among clinical samples and also bla
NDM among CRE. Antibiogram of carbapenem sensitive and resistant isolates
differs and susceptibility testing is mandatory for clinical isolates of
Enterbacteriaceae before initiation of treatment as few antibiotics are available
for infection due to this superbugs.
o Kirby bauer disc diffusion method is easy to perform and cost effective in
detection of carbapenamase resistance.
o Carbapenamase inactivation test is to be considered as a diagnostic tool for MBL
detection because of its rapidity,cost effectiveness and more sensitivity as well
as highly concordant with blaNDM PCR.
o Genotypic methods are essential for detection of blaNDM-1 gene to prevent the
dissemination of these pathogens.
o These detection methods have a vital role in recognizing these organisms as
epidemiologically important pathogens ,Quantifying the enormity of CRE within
the facility and regionally, identifying colonized and infected patients when
present in healthcare amenities and implementing intervention strategies
includes to establishment of awareness with health care workers and    upholding
of good hygienic practices and successful barrier precautions are to be followed
to prevent further transmission.
ANNEXURE – 1
1. Nutrient agar medium:
Composition
Ingredients gram/liter
Peptic digest of Animal Tissue 5.00
Sodium Chloride 5.00
Beef Extract 1.50
Yeast Extract 1.50
Agar 15.00
Twenty-eight grams of dehydrated nutrient agar medium was added
to 1000 ml of cold distilled water in a flask and boiled to dissolve the
medium completely. The medium was then sterilized in an autoclave at
1210C and 15 lbs pressure for 15 minutes. The sterile media were stored in a
refrigerator at 40C for future use.
2. MacConkey agar medium:
Composition - Ingredients gram/liter
Peptone 19.0
Lactose 10.0
NaCl 5.0
Na- Deoxycholate 1.0
Neutral Red 0.03
Crystal Violet 0.001
Agar 15.0
Fifty-two grams of dehydrated MacConkey agar medium was
suspended in 1000 ml of cold distilled water and boiled to dissolve the
medium completely. The solution was then sterilized by autoclaving at
1210C and 15 lbs pressure for 15 minutes.
3. Blood agar medium
Composition
Ingredients gram/liter
Heart infusion 500.00
Tryptose 10.00
Sodium chloride 5.00
Agar 15.00
Forty grams of the dehydrated blood agar medium was suspended in
1000 ml cold distilled water in a flask and boiled to dissolve the medium
completely. It was then sterilized by autoclaving at 1210C and 15 lbs
pressure for 15 minutes. The autoclaved materials were allowed to cool to a
temperature of 450C in a water bath. Defibrinated 5-10% sheep blood was
then added to the medium aseptically and distributed to sterile petri dishes.
Sterile media was stored in refrigerator at 40C for future use.
4. Muller Hinton agar medium
Composition
Ingredients gram/liter
Beef dehytrated infusion 300
Casein hydrolysate 17.50
Starch agar 17.00
Agar 17.00
Thirty-eight grams of dehydrated Mueller Hinton agar medium was
suspended in 1000 ml cold distilled water and boiled to dissolve the medium
completely. The solution was then sterilized by autoclaving at 1210C and 15
lbs pressure for 15 minutes. The autoclaved media was stored in the
refrigerator and used later.
5. McFarland Standard (0.5):
Reagents:
Sulphuric acid, 1%: To 100 ml of distilled water,1 ml of
conc.sulphuric acid is added. Barium chloride, 1.175%: To 100 ml of
distilled water, 1.175gm of barium chloride is added and mixed well.
To prepare McFarland 0.5 standards:
To 85 ml of 1% conc.sulphuric acid, 0.5 ml of Barium chloride is
added in a flask while constantly swirling the flask. Bring to 100 ml with
1% conc.sulphuric acid. Aliquot in test tubes and cap tubes tightly. Store in
the dark at room temperature for 3 months or longer.

ANNEXURE-II
PROFORMA
Name :
Age :
Sex :
OP/IP No :
Lab No :
Ward :
Complaints :
Clinical diagnosis :
Nature of Specimen :
Duration of hospital stay :
Antibiotics administered :
Investigation :
Biochemical tests : Indole, Citrate, Urease, Triple sugar iron,
Catalase, Oxidase
Antibiogram :
Piperacillin, Amikacin, Ceftriaxone, Cefotaxime, Ceftazidime,
Ciprofloxacin, Ofloxacin, Gentamicin, Ertapenam, Piperacillin with
Tazobactam, Ceftazidime with clavulanic acid, Colistin. Tigecycline
Screening test with Ertapenem
1.Disc diffusion test
2.E-test
Screenining test for metallo beta lactamase production:
1.Combined disc test
2.MHT
3.MBL E-test and
4.Carbepenemase inactivation test)
RT- PCR
COLOUR PLATE:1
A. MAC CONKEY AGAR PLATE SHOWING LACTOSE
FERMENTING COLONIES OF E.coli
B.NUTRIENT AGAR PLATE SHOWING MUCOLI COLONIES OF
KLEBSIELLA SPECIES
COLOUR PLATE ;2
A. MAC CONKEY AGAR PLATE SHOWING MUCOID LACTOSE
FERMENTING COLONIES OF KIEBSIELLA SPECIES
B.NULTRIENT AGAR PLATE SHOWING SWAMING OF PROTEUS
COLOUR PLATE:3
A.DISC DIFFUSION TEST: showing Ertapenem sensitivity
B.DISC DIFFUSION TEST: showing Ertapenem resistance
COLOUR PLATE:4
A.ERTAPENEM E-TEST: showing  Ertapenem resistance
B.COMBINED DISK DIFFUSION TEST: showing MBL production
COLOUR PLATE:5
A.MBL E-Test: showing MBL production
B.MODIFIED HODGE TEST:
COLOUR PLATE:6
CARBAPENEMASE  INACTIVATION TEST: showing MBL production
After  Incubation
COLOUR PLATE:7
A.THERMOCYCLER:
B.DNA EXTRACTION KIT:
COLOUR PLATE:8
REAL TIME PCR AMPLIFICATION CHART:
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1 ##10/365m
SNN-3 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 10 days
N R R R R R R R S R S S S S R R _ _ _ - -
2 ##13/365M
SNN-3 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 13days
N R R R R R R R S R S S S S R R _ _ _ - -
3 ##7/365m
SNN-3 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 7days
N R R R R R R R R R S S S S R R _ _ _ - -
4 ##8/365 F
SNN-1 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 8 DAYS
N R R R R R R R R R S S S S R R _ _ _ -
5 ##5/365M
SNN-3 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 7 DAYS
N R R R R R R R R R S S S S R R _ _ _ - -
6 ##4/365 F
SNN-1 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 4 days
N R R R R R R R S R S S S S R R _ _ _ _ _
7 ##6/365 F
SNN-3 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 6-days
y R R R R R R R R R S R S s R R p P p p P P
8 ##8/365M
SNN-3 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 8days
N R R R R R R R R R S S S S R R pNN N p N
9 ##4/365M
SNN-2 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 7days
y R R R R R R R R R S R S s R R PNN N p N
# ##7/365 F
SNN--3 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 18 Days
y R R R R R R R R R S R S S R S P P p P N P
# ##10/365F
SNN--2 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 10 days
N R R R R R R R R R S S S S R R _ _ _ _ _ _
# ##9/365M
SNN-2 BLOODK.oxytocaSEPSIS
Preterm.
LBW 9days
N R R R R R R R R R S S S S R R _ _ _ _ _ _
# ##7MonthsF
PICU BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 8 days
N R R R R R R R S R S S S S R R _ _ _ _ _
# ##6/365 F
SNN--2 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 6 days
N R R R R R R R S R S S S S R R _ _ _ _ __
# ##7/365 F
SNN-2 BLOODK.pneumoniaeSEPSIS
Preterm.
LBW 7 days
N R R R R R R R S R S S S S R R _ _ _ _ _
# ## 62 F
S-2 URINEE.coli UTI
POST 
SX 15 Days
N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 58 M
S-2 URINEE.coli UTI
POST 
SX 15 days
N R R R R R R R R R S R R R R S P P p p P P
# ## 70 M M-2 URINEE.coli UTI-CA CA  5 DaysN R R R R R R R R R S S S S R S _ _ _ _ _
# ## 2 M
PICU URINEE.coli UTI
SURGE
RY 6days
N R R R R R R R R R S S S S R S _ _ _ _ _
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AST pattern by agar diffusion
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AST pattern by agar diffusion
# ## 78 M M-2 URINEE.coli UTI-CA CA 4-DaysN R R R R R R R R R S S S S R S _ _ _ _ _
# ## 65 M S-2 URINEE.coli UTI-CA CA 5-daysN R R R R R R R R R S S S S R S _ _ _ _ _
# ## 34 M M-OP URINEE.coli UTI NIL NIL N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 70 M M-4 URINEE.coli UTI CA 6Days N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 75 M
S-6 URINEE.coli UTI
POSTS
URGER
Y 8days
N R R R R R R R R R S S S S R S _ - _ _ _
# ## 10 F
PAE.W URINEE.coli UTI
MALNU
ITRITIO
N 2days
N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 36 F IMCU URINEE.coli UTI NIL 5days N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 56 M
S-4 URINEE.coli UTI
POSTS
URGER
Y 5 days
N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 27 F
OG-2 URINEE.coli UTI
POSTS
URGER
Y 2days
N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 3 F
P.W URINEK.oxytocaUTI
URETE
RIC 
REFLE
X 13 Days
N R R R R R R R R R S R R S R R PN P P P P
# ##10 MonthsM
P.Sur URINEE.coli UTI
POST 
SURGE
RY 2days
N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 23 F S-5 URINEE.coli UTI NIL 4days N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 18 M
Uro.W URINEK.oxytocaUTI
URETE
RIC 
STRICT
UER 5days
N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 65 M
Uro.W URINEK.oxytocaUTI
POST 
SURGE
RY 5days
Y R R R R R R R R R S S S S R S _ _ _ _ _ _
# ## 65 M
Uro.W URINEK.oxytocaUTI
POST 
SURGE
RY 6Days
N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 10 M M.OP URINEE.coli UTI  NIL NIL N R R R R R R R R R S S S S R S _ _ _ _ _
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AST pattern by agar diffusion
# ##5MonthsM
MCH URINEE.coli UTI
POST 
SURGE
RY 7days
N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 75 M IMCU URINEE.coli SEPSIS DM 5days N R R R R R R R R R S S S S R S _ _ _ _ _
# ##5MonthsM
P.Sur URINEE.coli UTI
POST 
SURGE
RY 3Days
N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 3 M
P.Sur URINEE.coli UTI
POST 
SURGE
RY 2days
N R R R R R R R R R S S S S R S _ _ _ - _
# ## 60 F
URO-2 URINEK.oxytocaURETERIC COLIC
POSTS
URGER
Y 7days
N R R R R R R R R R R S S S R S _ _ _ _ _
# ## 3 M
PICU URINEE.coli UTI
POST 
SURGE
RY 4days
N R R R R R R R R R R S S S R S _ _ _ _ _
# ## 55 M
S-2 URINEE.coli UTI
POST 
SURGE
RY 8days
Y R R R R R R R R R R S S S R S _ _ _ _ _
# ## 74 M
S-1 URINEE.coli UTI-CA
POST 
SURGE
RY 9days
N R R R R R R R R R R S S S R S _ _ _ _ _
# ## 72 F
URO OP URINEE.coli UTI-CA
CATHE
TER NIL
N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 74 M IMCU URINEE.coli UTI DM 6Days N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 3 F
FCH URINEE.coli UTI
URETE
RIC 
REFLE
X 2days
N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 47 M
S-1 URINEK.pneumoniaeUTI
POST 
SURGE
RY 5days
N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 74 M IMCU URINEE.coli SEPSIS DM 4days N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 64 M M-4 URINEE.coli UTI DM 3Days N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 55 M M-2 URINEE.coli UTI DM 4days N R R R R R R R R R S S S S R S _ _ _ _ _
# ## 55 F S-2 PUSK.pneumoniaeNon healng ulcerDM 16 daysY R R R R R R R R R S R S S R S P P p p P P
# ## 45 M S-2 PUSP.vulgarisNon healng ulcerDM 19daysY R R R R R R R R R S R S R R R P P p p P P
# ## 55 M CAS.W PUSP.mirabilisNon healng ulcerDM 20 DaysY R R R R R R R R s S R S R R R PNN P P P
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AST pattern by agar diffusion
# ## 35 M NEP.W CAT,TIPK.pneumoniaeSEPSIS CKD 15 DaysN R R R R R R R R R S R S S R S P P p p P P
# ## 45 M
S-7 DRAIN FLUIDK.oxytocaSSI
POST 
SURGE
RY 3days
N R R R R R R R R R S S S S R S _ _ _ _ _ _
# ## 55 M S-2 PUSK.oxytocaNon healng ulcerDM 21 daysY R R R R R R R R R S R S S R R P P p P P P
# ## 59 F
PUL.W BRON.WASHE.coli Pneumonia
CHRON
IC 
LUNG 
DISEAS
E 12 Days
N R R R R R R R R R S R S S R S P P p p P P
# ## 50 F FS-1 PUSP.vulgarisNon healng ulcerDM 18 DaysY R R R R R R R R R S R S R R R P P p p P P
# ## 65 M S-2 PUSK.oxytocaNon healng ulcerDM 17 DaysY R R R R R R R R R S R S S R S PN P P p p
# ## 60 M S-2 PUSK.oxytocaNon healng ulcerDM 16 DaysY R R R R R R R R R S R R S R S P P p p P P
# ## 65 M M-4 PUSE.coli Abscess DM 7days N R R R R R R R R R S R S S R R P P N p P P
# ## 29 F
OG-2 pus K.pneumoniaeWound infection
POST 
SURGE
RY 9 Days
N R R R R R R R R R S R S S R S PNN N P P
# ## 10 M
PAED.SX Wound swabK.pneumoniaeWound infection
POST 
SURGE
RY 8days
N R R R R R R R S R S R S S R S PNN N P P
# ## 59 M M-4 SputumK.pneumoniaePneumoniaDM 15 daysY R R R R R R R R R S R S S R S P P p P P P
# ## 55 F S-2 PUSK.pneumoniaeNon healng ulcerDM 10daysY R R R R R R R R R S R S S R R P P p P P P
# ## 60 M S-2 pus P.mirabilisNon healng ulcerDM 8days N R R R R R R R S R S S S R R S _ _ _ _ _ _
# ## 35 M NEP.W Catheter tipK.pneumoniaeSEPSIS CKD 18 daysN R R R S R R R R R S R S R R R P P p P P P
# ## 65 M
S-3 pus K.pneumoniaeWound infection
POST 
SURGE
RY 7days
N R R R R R R R R R S S S S R R _ _ _ _ _ _
# ## 51 M IMCU pus K.oxytocaCELLULITISDM 16 daysY R R R R R R R R R S R S R R S P P p N P P
# ## 60 M M-4 pus K.oxytocaNon healng ulcerDM 8days N R R R R R R R S R S S S S R S _ _ _ _ _ _
# ## 65 F S-4 pus P.vulgarisNon healng ulcerDM 8days N R R R R R R R S R S S S R R S P _ _ _ _ _
# ## 55 M ORTHO-3 pus P.vulgarisWound infectionDM 9days Y R R R R R R R R R S S S R R S _ _ _ _ _ _
# ## 45 F S-2 puS P.vulgarisNon healng ulcerDM 10daysY R R R R R R R R R S R S R R R PNN P N P
# ## 55 F S-7 PUSK.oxytocaNon healng ulcerDM 11daysY R R R R R R R R R S R S S R R PNN N P P
# ## 19 F OG-2 PUSK.oxytocaNon healng ulcerDM 10daysN R R R R R R R R R S S S S R S _ _ _
# ## 52 M
ISCU PUSK.oxytocaWound infection
POST 
SURGE
RY 16 days
N R R R R R R R R R S R S S R R P P p P P P
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AST pattern by agar diffusion
# ## 30 F
ORTHO-3 PUSK.oxytocaWound infection
POST 
SURGE
RY 9days
N R R R R R R R S R S S S S R S _ _ _
# ## 60 M
THOR.M PUSK.oxytocaLUNG ABSCESS
CHRON
IC 
LUNG 
DISEAS
E 17 Days
Y R R R S R R R R R S R S S R R P P p P P P
# ## 46 M THOR.M SputumK.oxytocaPneumoniaDM 12daysN R R R R R R R S R S S S S R S _ _
# ## 27 F
LW.ICU PUSK.pneumoniaeWound infection
POST 
SURGE
RY 8days
N R R R S R R R R R S S S S R S _ -
# ## 30 M
BURNS .WPUSK.oxytocaBURNS BURNS 8days
N R R R R R R R R R S S S S R S _ _
# ## 63 M S-2 PUSK.pneumoniaeNon healIng ulcerDM 8days N R R R R R R R R R S S S S R S _ _
# ## 53 M CAS.W PUSP.mirabilisAbscess DM 8days N R R R R R R R R R S S S R R S _ _
# ## 47 M CAS.W PUSP.mirabilisAbscess DM 7days Y R R R R R R R R R S S S R R S _ _
# ## 49 F
S-5 PUSP.vulgarisWound infection
POST 
SURGE
RY 9days
N R R R R R R R R R S S S R R S _ _
# ## 50 F
S-2 PUSP.vulgarisWound infection
POST 
SURGE
RY 12days
N R R R R R R R R R S S S R R S - _
# ## 62 M S-OP PUSP.mirabilisNon healIng ulcerDM 11daysY R R R R R R R R R S S S R R S _ _
# ## 50 M S-3 PUSK.oxytocaNon healIng ulcerDM 17 DAYSN R R R R R R R R R S R S S R R P P p P P p
# ## 38 M S-3 PUSE.coli Abscess NIL 11daysN R R R R R R R R R S S S S R S _ _
# ## 46 M S-3 PUSE.coli Abscess DM 12daysN R R R R R R R R R S S S S R S _ _
# ## 44 M S-7 PUSK.oxytocaCELLULITISDM 18 daysY R R R R R R R R R S R S S R R PNN P N P
# ## 50 F S-4 PUSP.vulgarisAbscess DM 11daysN R R R R R S R R R S R S R R R PNN N P P
# ## 54 M CAS.W PUSK.oxytocaAbscess DM 10daysY R R R S R R R R R S R S S R S P P p N N N
# ## 55 M S-1 PUSK.oxytocaAbscess DM 16 daysY R R R S R R R R R S R S S R R P P p N P P
# ## 45 M S-5 PUSK.oxytocaAbscess DM 16 daysN R R R R R R R R R S R S S R R P P p P P P
# ## 61 M S-2 PUSK.oxytocaAbscess DM 8days Y R R R R R R R R R S S S S R S - - _
# ## 60 F
M-4 SPUTUMK.pneumoniaePneumonia
CHRON
IC 
LUNG 
DISEAS
E 12days
N R R R R R R R R R S S S S R S - _ _
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AST pattern by agar diffusion
# ## 55 F S-4 PUSK.oxytocaAbscess DM 11daysN R R R R R R R R R S S S S R S - _ _
# ## 11 M
P.W PUSK.oxytocaAbscess
MALNU
ITRITIO
N 10days
N R R R S R R R R R S S S S R S _ _ _
# ## 37 M S-7 PUSK.pneumoniaeCELLULITISDM 9days N R R R S R R S R R S S S S R S _ _
# ## 42 F SKIN OP PUSE.coli Abscess DM 9days N R R R R R R R R R S S S S R S _ _
# ## 55 M
S-1 PUSE.coli Abscess
POST 
SURGE
RY 10days
N R R R R R R R R R S S S S R S _ _
# ## 40 M CAS.W PUSK.pneumoniaeAbscess DM 10daysN R R R R R R R R R S S S S R S _ _
# ## 54 M
M-6 SputumK.oxytocaPneumonia
CHRON
IC 
LUNG 
DISEAS
E 9days
N R R R S R R S R R S S S S R S _ _
# ## 68 M M-4 PUSK.pneumoniaeAbscess DM 9days Y R R R R R S R R R S S S S R S _ _
# ## 41 M
S-4 PUSP.vulgarisAbscess
POST 
SURGE
RY 9days
N R R R R R S R R R S S S R R S _ _
# ## 55 M
OG-2 PUSE.coli Abscess
POST 
SURGE
RY 10days
N R R R R R R R R R S S S S R S _ _
# ## 24 F FS-2 PUSP.vulgarisAbscess NIL 11daysY R R R R R R R R R S S S R R S _ _
# ## 64 M
S-6 PUSP.vulgarisAbscess
POST 
SURGE
RY 9days
Y R R R R R R R R R S S S R R S _ _
# ## 43 F
OG-2 PUSK.oxytocaSSI
POST 
SURGE
RY 18 days
N R R R R R R R R R S R S S R R PNN N P N
# ## 26 F S-2 PUSK.oxytocaAbscess DM 11daysN R R R R R S R S R S S S S R S _ _
# ## 65 M S-2 PUSK.oxytocaAbscess DM 18 daysN R R R R R R R R R S R S S R S PNN N P P
# ## 60 M M-4 PUSK.pneumoniaeAbscess DM 9days N R R R R R R R R R S S S S R S _ _
# ## 65 M
S-4 SputumK.oxytocaPneumonia
CHRON
IC 
LUNG 
DISEAS
E 16 days
Y R R R R R R R R R S R S S R R P P p P P P
# ## 65 M S-3 PUSK.pneumoniaeAbscess DM 10daysN R R R R R R R R R S S S S R S _ _
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AST pattern by agar diffusion
# ## 51 M ISCU pus K.oxytocaNon healIng ulcerDM 11daysN R R R R R R R R R S S R R R S _ _ _
# ## 59 M
M-1 SputumK.oxytocaPneumonia
CHRON
IC 
LUNG 
DISEAS
E 9days
N R R R R R R R R R S S S S R S - _
# ## 80 M IMCU CSFK.pneumoniaeMeningitisDM 11daysN R R R R R R R R R S S S S R S _ - _
# ## 25 M
URO-1 URINEK.pneumoniaeURETERIC COLIC
POST 
SURGE
RY 9days
N R R R R R R R R R S S S S R S - _
# ## 60 F
OG-2 VAGINAL SWABK.oxytocaCervicitis
POST 
MENOP
AUSAL 8days
N R R R R R R R R R S S S S R S - _
# ## 10 F
PAED WD Wound swabK.oxytocaAbscess
MALNU
ITRITIO
N 8days
N R R R R R R R R R S S S S R S - _
# ## 10 M M.OP URINEE.coli UTI NIL 7days N R R R R R R R RNAS S S S R S - _
# ##5MonthsM
PAE.SX URINEE.coli UTI
POST 
SURGE
RY 10days
N R R R R R R R RNAS S S S R S - _
# ## 70 M
S-3 URINEE.coli BPH
POST 
SURGE
RY 11days
N R R R R R R R RNAS S S S R S - _
# ## 45 M
URO-2 URINEE.coli UTI
POST 
SX 12days
N R R R R R R R RNAS S S S R S - _
# ## 3 M
PICU URINEE.coli UTI
POST 
SURGE
RY 9days
Y R R R R R R R RNAS S S S R S - _
# ## 60 F
S-2 URINEK.oxytocaUTI
POST 
SURGE
RY 9days
N R R R R R R R RNAS S S S R S - _
# ## 3 M
S-1 URINEE.coli UTI
POST 
SURGE
RY 9days
N R R R R R R R RNAS S S S R S _ _
# ## 55 M
URO-2 URINEE.coli UTI
POST 
SURGE
RY 8days
N R R R R R R R SNAS S S S R S _ _
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AST pattern by agar diffusion
# ## 74 M
S-1 URINEE.coli UTI
POST 
SURGE
RY 10days
N R R R R R R R SNAS S S S R S - _
# ## 72 M URO-2 URINEE.coli UTI BPH 10daysN R R R R R R R SNAS S S S R S _ _
# ## 69 F URO URINEE.coli URETERIC COLICBPH 9days N R R R R R R R RNAS S S S R S _ _
# ## 24 M URO-2 URINEE.coli URETERIC COLICNIL 9days N R R R R R R S RNAS S S S R S _ _
# ## 7 F
PICU URINEE.coli UTI
POST 
SURGE
RY 8days
N R R R R R S R RNAS S S S R S _ _
# ## 25 M S-2 URINEE.coli UTI NIL 10daysN R R R R R R R RNAS S S S R S _ _
# ## 45 M
URO-2 URINEK.oxytocaURETERIC COLIC
POST 
SURGE
RY 11days
N R R R R R R R RNAS S S S R S _ _
# ## 57 M
S-1 URINEK.oxytocaUTI
POST 
SURGE
RY 12days
Y R R R R R R S RNAS S S S R S _ _
# ## 62 M
URO-2 URINEK.oxytocaBPH
POST 
SURGE
RY 9days
N R R R R R R S RNAS S S S R S _ _
# ## 45 M
S-1 URINEK.oxytocaURETERIC COLIC
POST 
SURGE
RY 8days
N R R R R R R R RNAS S S S R S _ _
# ## 76 M
URO URINEK.oxytocaBPH
POST 
SURGE
RY 9days
N R R R R R R R RNAR R S S R R P P p P P P
# ## 77 M M-1 URINEE.coli SEPSIS DM 8days N R R R R R R R RNAS S S S R S _ _
# ## 60 M M-4 URINEP.vulgarisUTI-CA DM 8days N R R R R R R R RNAS S S R R S _ _
# ## 70 M
URO URINEK.oxytocaBPH
POST 
SURGE
RY 9days
N R R R R R R R RNAS S S S R S _ _
# ## 70 F IMCU URINEE.coli SEPSIS DM 9days N R R R R R R R RNAS S S S R S _ _ _
# ## 45 F IMCU URINEE.coli SEPSIS DM 8days N R R R R R S R RNAS S S S R S _ _
# ## 26 F IMCU URINEE.coli SEPSIS NIL 11daysN R R R R R R S RNAS S S S R S _ _
# ## 26 F OG-2 URINEE.coli UTI NIL 10daysN R R R R R R R RNAS S S S R S _ _
# ## 65 F
LW.ICU URINEE.coli UTR.PROLAPSE
POST 
SURGE
RY 8days
N R R R R R R R RNAS S S S R S _ _
# ## 70 M URO.OP URINEK.oxytocaUTI BPH 8days N R R R R R R R RNAS S S S R S _ _
D
IA
G
N
O
S
IS
S
P
E
C
IM
E
N
A
g
e
W
A
R
D
S
P
E
C
IM
E
N
O
R
G
A
N
IS
M
D
IA
G
N
O
S
IS
R
IS
K
 F
A
C
T
O
R
S
H
O
S
P
IT
A
L
 S
T
A
Y
 D
U
R
A
T
IO
N
P
ri
o
r 
ex
p
o
su
re
 t
o
 c
a
rb
a
p
en
a
m
s
A
m
p
ic
il
li
n
(3
0
µ
g
)
C
ef
ta
zi
d
im
e(
3
0
μ
g
)
C
ef
o
ta
x
im
e(
3
0
μ
g
)
C
ef
tr
ia
x
o
n
e(
3
0
μ
g
)
G
en
ta
m
ic
in
(1
0
μ
g
)
A
m
ik
a
ci
n
(3
0
μ
g
)
C
o
tr
im
o
x
a
zo
le
ci
p
ro
fl
o
x
a
ci
n
D
o
x
y
cy
cl
in
e
T
ig
ec
y
cl
in
e
E
rt
a
p
en
a
m
A
zt
re
o
n
a
m
co
li
st
in
ce
ft
a
zi
d
im
e 
/C
la
v
u
la
n
ic
 a
ci
d
P
ip
er
a
ci
ll
in
-T
a
zo
b
a
ct
a
m
E
rt
a
p
en
a
m
 E
-t
es
t
M
o
d
if
ie
d
 h
o
d
g
e 
te
st
C
o
m
b
in
ed
 d
is
c 
d
if
fu
si
o
n
 t
es
t
M
B
L
 E
-t
es
t
C
a
rb
a
p
en
a
m
a
se
 i
n
a
ct
iv
a
ti
o
n
 t
es
t
P
C
R
S
.N
O
M
IC
R
O
 N
O
 
S
E
X
AST pattern by agar diffusion
# ## 23 F
OG-2 URINEK.oxytocaUTI
POST 
SURGE
RY 9days
N R R R R R R R RNAS S S S R S - _
# ## 56 M NEP.W URINEE.coli UTI CKD 9days N R R R R R R R RNAS S S S R S - _
# ## 50 M M-4 URINEK.oxytocaUTI CVA 8days N R R R R R R R RNAS S S S R S _ _
# ## 30 F M-1 URINEK.oxytocaUTI NIL 9days N R R R R R R R RNAS S S S R S _ _
# ## 37 F
URO URINEK.oxytocaURETERIC COLIC
POST 
SURGE
RY 7days
Y R R R R R R R RNAS S S S R S _ _
# ## 30 F M-5 URINEK.oxytocaUTI NIL 11daysY R R R R R R R RNAS S S S R S _ _
# ## 60 M FM-2 URINEK.oxytocaUTI DM 9days Y R R R R R R R RNAS R S R R S P P p P P P
# ## 1 M
PICU URINEK.oxytocaSEPSIS
POST.U
RETHR
AL 
VALVE 9days
N R R R R R R R RNAS R S S R S P P p P N P
# ## 56 M M-5 URINEE.coli UTI DM 9days N R R R R R R R RNAS S S S R S _ _
# ## 45 M
URO-2 URINEK.oxytocaURETERIC COLIC
POST 
SURGE
RY 8days
Y R R R R R R R RNAS R S S R S PNN N P P
# ## 35 M
URO URINEK.oxytocaURETERIC COLIC
POST 
SURGE
RY 11days
N R R R R R R R RNAS S S S R S _ _ _
# ## 24 M M-4 URINEE.coli UTI NIL 8days N R R R R R R R RNAS S S S R S _ _ _
# ##7/365M
SNN URINEK.oxytocaSEPSIS
Preterm.
LBW 7days
N R R R R R R R RNAS S S S R S _ _
# ## 50 F
URO-2 URINEE.coli URETERIC COLIC
POST 
SURGE
RY 9days
N R R R R R R R RNAS S S S R S _ _ _
# ## 60 M
S-4 URINEE.coli UTI
POST 
SURGE
RY 9days
N R R R R R R R RNAS S S  S R S _ _
# ## 48 F IMCU URINEE.coli SEPSIS DM 11daysN R R R R R R R RNAS S S S R S _ _
# ## 74 M URO-2 URINEK.oxytocaUTI BPH 11daysN R R R R R R R RNAS S S S R S _ _
# ## 65 F
URO-2 URINEK.oxytocaURETERIC COLIC
POST 
SURGE
RY 9days
N R R R R R R R RNAS S S S R S _ _
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AST pattern by agar diffusion
# ## 42 M
S-6 URINEE.coli UTI
POST 
SURGE
RY 9days
N R R R R R R R RNAS S S S R S _ -
# ## 55 M
URO URINEE.coli URETERIC COLIC
POST 
SURGE
RY 8days
N R R R R R R R RNAS S S S R S - -
# ## 62 M M-5 URINEE.coli UTI CVA 11daysN R R R R R R R RNAS S S S R S _ -
# ##10monthsM
PAED.SX URINEK.oxytocaUTI
POST 
URETH
AL 
VALVE 10days
N R R R R R R R RNAS S S S R S _ -
# ## 32 F
OG-2 URINEP.vulgarisUTI
POST 
SURGE
RY 9days
N R R R R R R R RNAS S S R R S _ -
# ## 40 F M-5 URINEE.coli UTI DM 8days N R R R R R R R RNAS S S S R S _ _
# ## 60 F
S-7 URINEE.coli UTI
POST 
SURGE
RY 8days
N R R R R R R R RNAS S S S R S _ _
# ## 56 F M-5 URINEE.coli UTI DM 10daysN R R R R R R R RNAS S S S R S _ _
# ## 21 F M-3 URINEE.coli UTI DM 10daysN R R R R R R R RNAS S S S R S _ _
# ## 49 M
URO URINEE.coli UTI
POST 
SURGE
RY 11days
Y R R R R R R R RNAS S S S R S _ _
# ## 70 F URO URINEE.coli UTI BPH 9days N R R R R R R R RNAS S S S R S _ __
# ## 73 M
S-2 URINEE.coli UTI
POST 
SURGE
RY 9days
N R R R R R R R RNAS S S S R S _ _
# ## 55 M
M-4 URINEE.coli UTI
POST 
SURGE
RY 9days
N R R R R R R R RNAS S S S R S _ _
# ## 42 M S-4 PUSE.coli Abscess DM 10daysY R R R R R R R R R S R S S R R PN p P P P
# ## 65 M S-3 PUSK.pneumoniae Nonhealing ulcerDM 18 daysY R R R R R S S S S S R S S R S P P p P P P
# ## 50 F S-2  biopsy TissueP.vulgarisNon healIng ulcerDM 15 daysN R R R R R S S S S S R S R R S P P P P P P
# ## 65 F S-4 PUSK.oxytocaAbscess DM 12 daysN R R R R R S S S S S R S S R S PNN N P P
# ## 70 M S-2 PUSE.coli CELLULITISDM 16 daysN R R R R R R R R R S R S R R S PNN P P P
# ## 65 M S-4 PUSK.oxytocaCELLULITISDM 10 DaysN R R R R R R R R R S R S s R S P P N P P P
# ## 46 F OG-2 URINEK.oxytocaUTI Post SX 16 daysY R R R R R R S RNAS R S S R S P P P P P P
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AST pattern by agar diffusion
# ## 76 M
URO URINEK.oxytocaUTI
POSTS
URGER
Y 15 days
N R R R R R R S RNAS R S S R S P P P P P P
# ## 36 M
URO-2 URINEK.oxytocaURETERIC COLIC
POSTS
URGER
Y 17 days
N R R R R R R R R R R R S S R S P P P P P P
# ## 70 M U.OP URINEK.oxytocaUTI CA NA Y R R R R R R R R R S S S S R S P _ _ _
# ## 62 F
S-2 URINEE.coli UTI
POST 
SURGE
RY 8 days
Y R R R R R R R R R S S S S R S P _ _ _
# ## 56 M Nephro URINEE.coli UTI CKD 7days N R R R R R R R R R S S S S R S P _ _
# ## 70 M
URO URINEE.coli UTI
POST 
SURGE
RY 6 days
N R R R R R R R R R S S S S R S P - _ -
# ## 40 M
URO URINEE.coli UTI
POST 
SURGE
RY 6 days
N R R R R R R R R R S S S S R S _ - _ _
# ## 56 M
S-4 URINEE.coli UTI
POST 
SURGE
RY 16 days
N R R R R R R R R R S R S R R S P P P P P P
